The University of San Francisco

USF Scholarship: a digital repository @ Gleeson Library | Geschke
Center
Doctor of Nursing Practice (DNP) Projects

Theses, Dissertations, Capstones and Projects

Spring 5-10-2019

Hepatitis C Treatment in High Risk Patients: Implementation of a
Successful Community Focused Program
Annie Pedlar
arpedlar@dons.usfca.edu

Jodie Sandhu DNP, FNP-C
University of San Francisco

Follow this and additional works at: https://repository.usfca.edu/dnp
Part of the Nursing Commons

Recommended Citation
Pedlar, Annie and Sandhu, Jodie DNP, FNP-C, "Hepatitis C Treatment in High Risk Patients:
Implementation of a Successful Community Focused Program" (2019). Doctor of Nursing Practice (DNP)
Projects. 172.
https://repository.usfca.edu/dnp/172

This Project is brought to you for free and open access by the Theses, Dissertations, Capstones and Projects at USF
Scholarship: a digital repository @ Gleeson Library | Geschke Center. It has been accepted for inclusion in Doctor of
Nursing Practice (DNP) Projects by an authorized administrator of USF Scholarship: a digital repository @ Gleeson
Library | Geschke Center. For more information, please contact repository@usfca.edu.

Running head: HCV OUTREACH TREATMENT PROGRAM

Hepatitis C Treatment in High Risk Patients: Implementation of a Successful Community
Focused Program
Annie Pedlar, DNP
University of San Francisco
DNP Committee Chair: Dr. Prabjot (Jodie) Sandhu, DNP, MSN, FNP-C, RN, PA-C, CNL
DNP Committee Member: Dr. Wanda Borges, PhD, RN, ANP-BC

1

HCV OUTREACH TREATMENT PROGRAM

2

Section I: Acknowledgements
The journey of the DNP program has been nothing but exhilarating. I am forever grateful
for the skills and knowledge I have attained, and feel I have grown both professionally and
personally. I hope to one day become as knowledgeable and as effective of a healthcare leader as
many of the professors I have been honored to learn from.
The completion of my DNP project would not have been possible without my advisor and
chair, Jodie Sandhu. Words cannot describe enough my gratitude for Dr. Sandhu’s support,
guidance and encouragement. I am absolutely blessed to have Dr. Sandhu in my life, and could
not imagine it any other way. Thank you.
I also want to thank the staff (providers, nurses, and counselors) at BAART Turk clinic
for supporting me during the creation, implementation, and evaluation of this DNP project. I am
forever grateful for your patience and time, especially Cara Nalagan, NP who was fantastic in all
ways possible and imaginable.
Naturally, I want to thank my mom, dad, and sister for their support and encouragement.
I would certainly not be where I am today without their love. And last, but not least, I want to
thank my classmates. I am thrilled to have been part of such a great group of people that I am
proud to be in the same cohort with. Thank you all.

HCV OUTREACH TREATMENT PROGRAM

3

Abstract
Background: The city of San Francisco boasts a high rate of hepatitis C infection (HCV) among
IV drug users indicating the need for a hepatitis C treatment program. It is estimated that over
two-thirds of people who are actively infected with HCV are IV drug users (EndHepCSF, 2017),
and in 2017 the San Francisco Department of Public Health (SFDPH) estimated that there are
22,500 active people who inject drugs (PWID) in SF (SFDPH, 2017). With the presence of a
wide population of IV drug users in SF there is an identified need for intervention to treat this
high-risk patient population.
Methods: After identification of a significant population of HCV infected patients in a
community clinic, the latest evidence for HCV treatment was used to develop and pilot a
practical HCV treatment program using glecaprevir/pibrentasvir (Mavyret). The pilot was aimed
at testing a protocol in primary care, utilizing evidence based strategies.
Results: A total of 6 patients were enrolled in the pilot. There was a successful response rate
(100% SVR) among the treatment group, supporting the use of single drug treatment with
observed therapy in high risk populations.
Conclusion: The results of the project demonstrated that a standardized hepatitis C treatment
program is highly efficacious and can be delivered in primary care settings to patients who are
high risk.

Keywords: HCV, PWID, barriers, adherence, treatment, recommendations, education,
awareness, resources, increase rates.
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SECTION II: Introduction
Background/Knowledge
Hepatitis C virus (HCV) is the most common chronic blood-borne disease in the United
States. HCV is a chronic RNA virus that causes progressive liver damage, and is the leading
cause (Razavi et al., 2013) of liver cirrhosis, hepatocellular carcinoma (liver cancer), and liver
transplantation (Manns, et al., 2017). Patients who are at higher risk of being infected are: people
who inject drugs (PWID) (accounting for over half of the active HCV population), men who
have sex with men (MSM), and baby boomers (EndHepCSF, 2017). Other high risk groups are
people with prior injection use, people living with HIV, transgender women, and people with a
history of incarceration (EndHepCSF, 2017). HCV is transmitted through contact with
contaminated blood of an infected person. Modes of transmission are contact with infected
needles (more common in the healthcare setting), tattoos or body piercings using non-sterile
tools, current or past IV drug use (sharing needles), blood transfusions or organ transplants
before 1992, and contaminated equipment and needles used for dialysis in the healthcare setting
(Gilead, 2015). Symptoms of HCV include fever, fatigue, loss of appetite, nausea and vomiting,
abdominal pain, dark urine, gray-colored bowel movements, joint pain and jaundice (yellow hue
of skin). HCV symptoms may not appear for years, or even decades. Even though the patient
may not feel sick, HCV can be silently doing harm (Gilead, 2015). HCV was once without a
cure, but recognition that HCV is a treatable, curable, and a preventable disease, and that
treatment can reduce healthcare costs of the comorbidities that are associated with HCV, such as
liver cirrhosis and cancer, have changed this belief. Cured HCV is represented by a sustained
virologic response (SVR) of the patient, measured 12 weeks after treatment completion (known
as SVR12). Most recently the development of treatments has successfully demonstrated a cure
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for this virus and the possibility of avoiding long term consequences. On a global level, between
64 and 103 million people are chronically infected with HCV (Manns, et al., 2017). In the U.S.,
HCV affects over 3 million people (Gilead, 2015), and has surpassed all other nationally
notifiable infectious diseases combined as a cause of death in the U.S. (EndHepCSF, 2017).
There is an estimated 12,000 people living with active HCV in SF (EndHepCSF, 2017),
indicating there is a continuing need for HCV awareness, education, and treatment in
communities.
HCV was discovered 30 years ago in 1989 by scientists at the Centers for Disease
Control and Prevention (CDC), National Institutes of Health (NIH) and industry (CDC, 2014). In
1991, the Food and Drug Administration (FDA) approved the very first drug to treat HCV (CDC,
2014). Unfortunately, the initial treatment resulted in very few patients clearing the virus (CDC,
2014). Since 1991, a total of 16 antiretroviral medications (two of which have been removed
from the market) have been developed (Spach & Kim, 2018), leaving 14 currently active HCV
drugs on the market. The medications initially used to treat HCV were combinations of ribavirin
and interferon and had many side effects, such as nausea and vomiting, weight loss, depression,
insomnia, flu-like symptoms, diarrhea, headache, malaise, joint and muscle pain, and exhaustion
(Wessels, 2018). Over the course of time, the medications to treat HCV have established a lower
side effect profile, and have gone from combination drug treatments to single drug treatments,
like Mavyret. Mavyret belongs to a new class of direct acting antivirals (DAA) for HCV, and is
regarded as being very cost-effective, having the best tolerance and treatment adherence rates
due to the low side-effect profile, and is able to treat all six genotypes. The newer treatment
options are very promising, but also come at an incredibly high cost to the health care system. In
February 2017, 29% of San Francisco Health Plan’s (SFHP) pharmacy budget (representing only
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0.2% of pharmacy claims) was used for Hepatitis C treatment (San Francisco Hepatitis C Task
Force, 2017). Since HCV is a particularly outstanding health care problem in SF due to a higher
population of high-risk patients (EndHepCSF, 2017).
Of the 3 million people in the U.S. who are actively infected with HCV, PWID make up
68% of that population (EndHepCSF, 2017). Since PWID makes up a very large percentage of
the HCV population, it is important that this specific patient population be treated and not turned
away from receiving care and treatment. In the past, this specific patient population had been
turned aware from receiving HCV treatment due to patient fear of stigmatization by providers
and society, provider fear that the patient would not complete treatment, and provider concerns
that patients would reinfect themselves after being cured, indicating it would be a waste of
resources to treat PWID (Grebely, Oser, Taylor & Dore, 2013). When this patient population is
left untreated healthcare costs and demands increase in other ways due to hepatic and nonhepatic comorbidities, which include insulin resistance, cryoglobulinemia, dermatologic disease,
renal disease, cardiovascular disease, and chronic fatigue (EndHepCSF, 2017). According to End
Hep C SF (2017), the benefits of HCV treatment are a 90% risk reduction in liver transplant and
liver-related mortality, a 70% decrease in liver cancer, and 50% of patients who have liver
cirrhosis will have improvement in their fibrosis. The estimated costs of comorbidities in the US
associated with HCV (liver cirrhosis, hepatocellular carcinoma, liver failure, and liver
transplants) is $6.5 billion per year and will peak in 2024 to $9.1 billion (Razavi et al., 2013).
Razavi et al. (2013) states it is possible to reduce HCV infection and, in turn, the costs of
comorbidities associated with HCV through active management of this viral infection. The
initiation of HCV treatment in PWID is overall more cost-effective and can prevent further liverrelated mortality when treated in the early stages (EndHepCSF, 2017).
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Various direct-acting antivirals (DAAs) have been approved by the FDA and are
available on the market. DAAs target three proteins involved in the HCV life cycle: the NS3/4A
protease, the NS5A protein, and the RNA-dependent RNA polymerase NS5B protein. A
combination of two or three of these medications can cure HCV in >90% of patients, including
patients who have been difficult to treat in the past (Manns, et al., 2017). In 2013, Sovaldi was
one of the first new HCV drugs, also classified as a direct acting anti-viral, that was approved by
the FDA. The listing price for Sovaldi was $84,000 for a 12-week treatment, but the price has
since come down due to public health programs, like Medi-Cal, being able to negotiate the cost.
In more recent years, the HCV drug Zepatier, costing $54,600 for a course of treatment, and
Mavyret, costing $26,400, are similar to Solvadi, Harvoni, and Viekira Pak in that they have
fewer side effects, work faster, and are more effective in curing HCV than the older HCV drug
interferon (Bartolone, 2018). The total cost of Mavyret has been priced by AbbVie (the
manufacturer of Mavyret) for $13,200 per month, or $26,400 per eight-week course of treatment
for each patient (Shye, 2017).
Table 1
Drug Comparison Table
Brand
Generic Name
Name
Mavyret

Glecaprevir/pibrentasvir

Genotype
Treated

Side Effects

1-6 (all
genotypes)

Mild; fatigue,
headaches,
and pruritus in
the first two
weeks of
starting
treatment.
Side effects
resolved after
the initial two
weeks.

Cost for
8-week
course
therapy
$26,400
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Table 1
Drug Comparison Table
Brand
Generic Name
Name

Genotype
Treated

Viekira
Pak

Ombitasvir/paritaprevir/riton
avir plus dasabuvir

1

Sovaldi

Sofosbuvir

1-4

Zepatier

Grazoprevir/elbasvir

1,4

Harvoni

Ledispavir/sofosbuvir

1,4,5,6

Table 1

Side Effects

Mild; fatigue,
headaches,
nausea,
pruritus, skin
reactions,
insomnia, and
asthenia (loss
of strength)
Symptomatic
bradycardia if
taken with
amiodarone;
fatigue,
headaches,
nausea, fever,
chills,
arthralgia
(joint pain),
anemia,
neutropenia;
cannot be
taken by
pregnant or
trying-to-be
pregnant
women
Mild; fatigue,
headaches,
nauseas,
insomnia,
diarrhea.
Mild; fatigue,
headache,
nausea,
diarrhea,
insomnia

Cost for
8-week
course
therapy
$83,320

$77,760

$54,600

$63,000
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Problem Description
According to the U.S. Census conducted in 2015, 2.5% of all people living in SF have
HCV (EndHepCSF, 2017). Among this percentage, 68% of the active cases are made up by
people who inject drugs, 14% by men who have sex with men, and baby boomers make up the
other 38% (EndHepCSF, 2017). The estimated percentage of people living with HCV in SF
(2.5%) is significantly higher than the national percentage of 1.7% (EndHepCSF, 2017). It is not
a surprise since that the burden of HCV disease is greater in SF since a higher proportion of the
residents of the city are in the groups at highest risk for HCV. San Francisco has the highest liver
cancer rate in the nation, most of which is attributed to high rates of Hepatitis B and C virus
infections (San Francisco Hepatitis C Task Force, 2017).
Gap Analysis
A gap analysis was conducted in the city of San Francisco at a local community clinic
that serves a significant population of PWID and are considered at higher risk for contracting
HCV. A comparison of the current state to the desired future state was done in order to determine
what was needed to achieve the prospective goal (Appendix C). According to McGown and
Fried (2011), these high-risk populations often do not seek treatment for several reasons.
Mentioned reasons include: poor awareness/education, lack of interest in seeking treatment
since they are asymptomatic, lack of medical coverage, failure of the provider to screen
the patient, patient non-adherence to the medication regimen, provider failure to refer the
patient, limited specialist availability (patients who present with a more complicated
clinical picture such as liver cirrhosis), patient fears and misunderstandings,
stigmatization, substance abuse, transportation challenges, and communication
difficulties (no cell phone and/or reliable address).
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The most common concern seen in patients that hindered their interest in receiving
HCV care and treatment was the side effects they could encounter with the medication.
The next most common identified gap was patients did not feel they need to be treated for
HCV if they were asymptomatic. These concerns were addressed during their primary
care visits with the providers at to provide education that the newer HCV medications,
such as Mavyret, have minimal to no side effects, and that even though they may feel
healthy right now, the HCV is actively causing harm to their liver, and by the time
symptoms are experienced damage has already been done.
Setting
BAART Programs for the treatment of opioid addiction and primary care are nationwide
group of community health centers with a total of 29 locations (BAART, 2019). BAART Turk is
a California Community Clinic and is a member of the San Francisco Community Clinic
Consortium (SFCCC). Six of the BAART locations are in the San Francisco Bay Area (BAART,
2019). The populations served are people recovering from substance abuse and pursuing to
achieve life-time recovery, and underserved populations (low-income and/or homeless residents
of the surrounding area). BAART provides substance use counseling, the initiation, maintenance,
and monitoring of methadone and buprenorphine administration, and low-cost primary care and
preventive health services. Opioid use disorder treatment, and mental health and primary care
services are offered in one convenient location at BAART on Turk Street (BAART Turk)
(BAART, 2019). Of the 400-600 patients who are dosed daily for methadone, 115 of these
patients are eligible to be treated for HCV. Currently, there are a total of 35 staff at BAART
Turk. The staff consist of: one medical assistant who performs lab draws, takes patient vital
signs, gives injections, rooms patients, and performs nebulizer and wound care treatments; three

HCV OUTREACH TREATMENT PROGRAM

14

registered nurses who dispense medications to patients; 14 substance abuse counselors; two
nurse practitioners (NPs) and two physicians for provider appointments; two front desk
receptionists to check-in patients; two counseling supervisors; one on-site clinic director; one
mental health director; one psych NP; one mental health nurse; four interns either training to be
mental health counselors or doing their one-year internship for a PsyD program; one
administration assistant; and one security guard. The insurances that are accepted at BAART
Turk are Anthem Blue Cross of California, Medi-Cal, private insurance (Anthem Blue Cross,
Kaiser Permanente, Veterans, and other private insurance with pre-authorization), and TriWest
(Health Net Federal Services), and San Francisco Health Plan (SFHP) (BAART, 2019).
BAART Turk Street Clinic is well positioned to contribute to the treatment and
eradication of HCV in PWID. According to the San Francisco Department of Public Health
(SFDPH) (2017), 31% of the 22,500 people who are active IV drug users in SF reside in the
Tenderloin, making the location of this clinic in the heart of the Tenderloin very convenient and
has proven to be highly effective in treating this patient population. BAART Turk has a large
patient population who is at risk for having and transmitting HCV (EndHepCSF, 2016).
Majority of patients seen at BAART Turk are there to receive methadone treatment. The
patients usually come in for their medication daily and it is distributed to them by the nursing
staff. There are a total of two physicians and two nurse practitioners on site who see patients for
both primary care and specialized methadone care. When BAART Turk did not have a HCV
treatment protocol, they reached out to the San Francisco Health Plan (SFHP) and created a
partnership to receive a grant for the treatment of infected individuals over the next two years. It
was projected that the HCV grant would provide treatment to hundreds of high-risk patients by
September 2018, and will achieve a cure for 85% of participating patients by the year 2020
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(Kletter, 2018). The grant indicated that the antiretroviral Mavyret be used for the treatment of
HCV at BAART Turk due to its low side-effect profile, ability to treat all genotypes, and lowcost compared to other HCV treatment medications on the market (Abbvie, 2018). Costs of
Mavyret were covered by the grant. The stakeholders of the project are Dr. Deb Borne (chief
organizer, lead physician), Dr. Brian Clear (project oversight as the medical director of BAART
Turk), Cara Nalagan, NP (project coordinator, lead NP), and Annie Pedlar, NP student intern as
the DNP author. The intervention is applicable to the patients at BAART due to the high-risk
profile of patients with homelessness and IV drug abuse (IVDA). The implementation of the
HCV treatment program at BAART Turk was authorized by the San Francisco Department of
Public Health (SFDPH), SFHP, and by the medical director, Dr. Brian Clear, of BAART Turk.
The collaboration between USF and BAART Turk was developed through a memorandum of
understanding (MOU), and the project proposal, as stated in the statement of determination
(Appendix A) was approved by committee chair, Dr. Prabjot (Jodie) Sandhu and my role as DNP
author was authorized by Dr. Brian Clear, medical director of BAART Turk who has written a
letter of support (Appendix B).
BAART would like to support efforts to target hard-to-reach populations, such as those
who use IV drugs and/or with unstable housing, to improve treatment efficacy, and secondarily
reduce rates of Hepatitis C transmission in SF. Since their patient population is high-risk for
having and becoming infected with HCV, the implementation of a HCV treatment program
would largely benefit the primary care and methadone patients seen at BAART.
Need for Evidence Based Intervention
Due to its strength in treating HCV regardless of genotype, accessibility, low side effects,
and short treatment period, the treatment of HCV with Mavyret is highly recommended as a first-
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line choice drug for high-risk populations. Given that Mavyret is highly efficient and effective, it
is an ideal treatment model and the best drug choice for a HCV treatment plan or protocol in a
community setting.
Search Process
A systematic search was conducted in June-September 2018 based on the PICO question:
In patients with active hepatitis C virus (HCV), will treatment with the antiviral medication such
as glecaprevir/pibrentasvir (Mavyret) compared to no treatment result in a cure rom HCV,
demonstrated by attaining a sustained virologic response (SVR). Furthermore, investigation of
best practices and research related to evaluate the cost of HCV drugs and access issues, and
educational barriers to HCV treatment was also conducted. The keywords used in the search
process included: hepatitis C, Mavyret, SVR, SVR12, treatment, efficacy, effectiveness, IVDA (IV
drug abusers), PWID (people who inject drugs), OAT (opioid agonist therapy), methadone,
clinic, primary care setting, costs, San Francisco, benefits, risks, burden, barriers, access, and
comorbidities. CINAHL, PubMed, Cochrane, Scopus, and Google Scholar were the databases
searched. A gray search of the literature was also conducted on Dynamed, UptoDate, Google,
Medscape, and Epocrates. The search process yielded a total of 150 articles. Articles were
selected for review if they met the inclusion criteria: current literature published between 2010
and 2018, articles written in English, subjects being treated for HCV with antivirals, subjects
being treated for HCV with Mavyret. The articles that were excluded were ones not written in
English and articles that were written before 2010. While there were no scholarly articles
available which compared the various antiretrovirals available for HCV treatment, the SFHP
selected Mavyret as the drug of choice for two specific reasons – first, its cost compared to other
medications is significantly lower (see Background section above), and second, patient
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adherence tended to be higher due to fewer side effects. A total of 10 qualified articles were then
selected for final review. The evidence was rated using the Johns Hopkins Evidence Rating tool
(Appendix J).
Review of the Evidence
The treatment options for HCV have dramatically progressed from poorly tolerated and
moderately successful interferon-based therapies, to highly effective all-oral interferon-free drug
regimens (Abutaleb, Kottilil, & Wilson, 2018). The available studies used for the literature
review of Mavyret all support the fact that it is highly efficacious, and that due to its low sideeffect profile it is tolerated well and ultimately the best choice for patients who are in opioid
agonist therapy (OAT) and treated with methadone.
Mavyret Efficacy
Mavyret is the drug of choice in treating HCV patients at BAART Turk because it can
treat any genotype of the HCV and has little to no side effects. Voelker (2018) reviews clinical
trials, in which 2300 adult patients with HCV genotypes 1-6 showed that 92% who had received
Mavyret for 8,12, or 16 weeks had no detectable virus in their blood work 12 weeks after
treatment had ended (SVR12), indicating they were cured. The results of the study strongly
support the use and effectiveness of Mavyret and suggest that this DAA should be used to treat
all patients with HCV.
In a study done by Asselah, et al. (2018) called the SURVEYOR –II, after 8 weeks of
treatment with Mavyret, there was an SVR12 produced in 98% of those infected with HCV
genotype 2, and in 93% of the patients infected with genotypes 4,5, and 6; and after 12 weeks
time an SVR12 was produced in 99.5% of genotype 2 patients and 99% in genotypes 4,5, and 6.
A total of 568 patients took part in this multi-level study, two studies being open label, and
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single-arm, and the other being a randomized, double-blind, placebo-controlled study. The
findings of the studies suggest that the safety and efficacy of 8 and 12 weeks’ treatment with
Mavyret is highly effective, which supports the use of this drug to treat patients living with HCV.
A partially randomized, open-label, multicenter, phase 3 study trial conducted by Wyles,
et al., (2017), assessed the efficacy of Mavyret in treating patients with HCV of genotype 3, and
had prior treatment experience and/or compensated liver cirrhosis. This specific patient
population is traditionally difficult to treat due to limited treatment options given the complexity
of their HCV status. A total of 131 patients participated in the study. Of the treatment
experienced patients without cirrhosis, an SVR12 was attained by 95% of patients treated with
Mavyret for 12 or 16 weeks. The patients who had cirrhosis and were treatment-naïve achieved
an SVR12 of 98% at 12 weeks, and 96% of the patients with prior treatment experience attained
an SVR12 who were treated for 16 weeks. Based on these results, this patient population
achieved high rates of SVR12 and supports the efficacy and safety of Mavyret (Wyles, et al.,
2017).
The EXPEDITION-1 study by Forns, et al., (2017) is a phase three, single-arm, openlabel, multicenter study at 40 sites in Canada, Belgium, Germany, Spain, South Africa, and the
US. All patients were over 18 years of age, had chronic HCV with genotypes 1,2,4,5, or 6,
compensated cirrhosis, and were either treatment-naïve or were treatment exposed to interferon
and/or ribavirin and had a failed virologic response. A total of 146 patients were in the study, and
an SVR12 of 99% was achieved at the end of the 12-week course treatment of Mavyret,
indicating high efficacy rate of this medication (Forns, et al., 2017).
In the EXPEDITION-2 study, done by Rockstroh et al., (2018), 153 patients with HCV
and either genotypes 1-6, and HIV coinfection were treated with Mavyret. Patients with
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compensated liver cirrhosis (16 total) were also included. Some of the patients were treatmentnaïve and others were treatment experienced with sofosbuvir, ribavirin, or interferon and
antiretroviral naïve or on a stable antiretroviral regimen for their HIV. Treatment experienced
genotype 3 patients were excluded. EXPEDITION-2 is a phase 3, multicenter, open-label study
assessing the efficacy of Mavyret for 8 to 12 weeks. An SVR12 was achieved in 98% of 137
patients who were treated for 8 weeks. The results of this study have concluded that Mavyret
treatment for 8 weeks in non-cirrhotic and 12 weeks in cirrhotic patients is highly effective and
well-tolerated by patients with HCV and HIV coinfection (Rockstroh, et al., 2018).
The study named MAGELLAN-1 by Poordad, et al. (2017) focused on 50 HCV patients
who were of genotype 1, no cirrhosis, and had prior virologic failure to HCV direct-acting
antivirals (DAA). It is a phase-2, open-label study with three arms. Two arms were treated with
just Mavyret of different doses (arms A and B), and the third arm was treated with Mavyret in
addition to ribavirin (arm C). The SVR12 was at least 95% in arms A and B, and 86% in arm C.
Based on these values, Mavyret was highly effective and well tolerated in patients with HCV
genotype 1 infection who had prior virologic failure with other DAA therapies (Poordad, et al.,
2017).
The CERTAIN-1 study done in Japan is a phase 3, open-label, multicenter study which
assessed the safety and efficacy of Mavyret in 181 Japanese patients with HCV, genotype 1, with
or without cirrhosis (Chayama, et al., 2017). The patients without cirrhosis were treated for 8
weeks, and the patients with cirrhosis were treated for 12 weeks. An SVR12 was attained by 128
of the 129 (99.2%) non-cirrhotic patients, and 52 of the 52 (100%) cirrhotic patients. The results
of this study demonstrate a high efficacy and tolerance for Mavyret in these patients, indicating
strong support for future patients to be treated for HCV with this drug (Chayama, et al., 2017).
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In the SURVEYOR-I and SURVEYOR-II studies by Kwo, et al. (2017), HCV patients
with genotypes 1-6 were treated with Mavyret for either 8 or 12 weeks. These patients had no
cirrhosis, were treatment-naïve, or treatment exposed to interferon and ribavirin. The studies are
open-label, multicenter, dose-ranging trials of 449 patients. For the 12-week treatment, SVR12
was attained in 97-100% of the patients, and 97-98% was achieved in the patients with the 8week treatment. The results support the effectiveness of Mavyret in treating patients who have
HCV with genotypes 1-6 and no cirrhosis as evidenced by the high rate of SVR12 (Kwo, et al.,
2017).
Gane, et al. (2016), conducted two studies that were open-label and phase 2. Twentyseven patients with chronic HCV with genotype 1, and 55 patients with genotype 3, and all had
compensated liver cirrhosis. The majority of these patients were treatment-naïve (84%) and male
(65%). A 12-week course of Mavyret was given to treatment-naïve patients, and a 16-week
course was for those who had exposure to prior treatment. The overall result yielded a SVR12 of
96-100% between both arms of the study. The only adverse effects experienced were headache,
fatigue, and nausea. All in all, Mavyret was well tolerated by the patients in this study and is
recommended for future use in treating HCV (Gane, et al., 2016).
Barriers to HCV Treatment
An important aspect to determining successful treatment in HCV patients is to account
for any potential barriers, especially in this high-risk population. Evaluating the barriers will help
control the pitfalls of treatment and allow for a better exploration of the gaps perceived in
providing care to HCV patients. The patients who have experienced barriers to access and
treatment for HCV are typically ones that are past or present IV drug abusers.
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Grebely, et al. (2008) distributed surveys to 188 HCV positive illicit drug users focusing
on the barriers associated with IV drug users. It was discovered that the major reasons for not
seeking HCV treatment were lack of information about HCV or knowledge that treatment was
available (23%), the absence of symptoms (20%), and the perceived side effects of treatment
(14%) (Grebely et al., 2008). In this study, it was observed there was a low uptake of HCV
treatment, but a high willingness to receive therapy. Based on the findings it is recommended
that there be an increased focus on improving education about the long-term consequences of
untreated HCV and the availability of effective treatment to expand HCV treatment among illicit
drug users (Grebely et al., 2008).
A systematic review conducted by Grebely, Oser, Taylor and Dore (2013) indicated that
HCV treatment uptake among people who inject drugs (PWID) will not increase unless the
barriers of HCV education, screening, evaluation, and treatment are addressed. Specific barriers
identified and addressed in this review were: systems-level (lack of screening, treatment and
evaluation guidelines), practitioner-level (withholding treatment because of perceptions about
poor treatment adherence, ongoing substance abuse, relapse to substance abuse, risk of
exacerbating comorbid psychiatric disease and potential risk of reinfection), and patient-level
(poor knowledge of HCV and the long-term consequences on health, and inaccurate perceptions
of HCV treatment side effects) (Grebely, Oser, Taylor & Dore, 2013). The studies reviewed have
shown that accurate guidelines to treatment initiation, monitoring and evaluation, and enhanced
patient and provider education can increase HCV treatment uptake.
The evidence strongly suggests that adherence to HCV treatment in patients who are
being treated with opioid agonist therapy (OAT) and are recently active or currently active
people who inject drugs (PWID) can be achieved, and that this patient population can achieve an
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SVR (Grebely et al., 2016). According to Grebely, Oser, Taylor, and Dore (2013), a history of
IV drug use (including recent drug use) does not compromise adherence or treatment completion
or SVR, and that occasional drug use during treatment did not affect outcomes. Directly
observed treatment promotes the most adherence in this patient population, and this approach
should be utilized whenever possible (Schutz et al., 2018).
There is strong evidence indicating that if the above listed barriers are addressed that
treatment uptake and overall success of HCV treatment will increase and less healthcare burdens
will be seen.
Theoretical Framework
The theoretical frameworks that will guide the development and implementation of this
project are the HBM (Health Belief Model) and EBM (evidence based model). Their theoretical
and psychological models help guide health promotion and treatment of current and future
healthcare issues. These two theoretical frameworks will provide the support to integrate change,
provide changes in behavior for both patients and staff, and utilize evidence as a tool to promote
a community based treatment model.
The Health Belief Model (HBM) was created in the 1950’s by social psychologists
Hochbaum, Rosenstock, and Kegels (1952) to help the U.S. Public Health Service determine
why medical screening programs that they offered were not successful (Turner, Hunt, DiBrezzo,
& Jones, 2004). The underlying thoughts of HBM is that behavior about and towards health
stems from personal beliefs and perceptions about a disease and the approaches used to treat the
disease (Glanz, Rimer, & Viswanath, 2002).
There are four perceptions that lead to the structures of the theory, which are: perceived
susceptibility, perceived severity, perceived benefits, and perceived barriers. The HBM is based
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on the idea that 1) people will make a health-related decision and take-action if they feel that a
negative health condition can be avoided, like hepatitis C; 2) the person has an optimistic thought
and expectation that by using such endorsed health action the person will be prevented from
experiencing a situation that negatively affects their health; and 3) the person feels confident and
comfortable enough to carry out the health action (Glanz & Rimer, 1997). Being able to
understand the factors that affect behavior compliance can help healthcare providers influence
positive health outcomes for the patients receiving care. The HBM will guide the project at
BAART Turk to identify the perceived threats and barriers that patients may have and possibly
encounter during treatment, and understand how to avoid these hindrances to promote that best
patient and overall project result outcomes.
Sackett (2014) defines EBM as the “conscientious, explicit, and judicious use of current
best evidence in making decisions about the care of individual patients”. The EMB was created
to develop and promote an “explicit and rational process for clinical decision making that
deemphasized intuition and unsystematic clinical expertise while emphasizing the importance of
incorporating the best research findings into clinical care” (Satterfield, et al., 2009). Creating
individualized treatment regimens for diseases, like HCV, using this model will provide the
patient the utmost effective and safe care. The foundation of the EBM model will guide
providers to create individualized approaches for each patient to promote the most successful and
effective response to the treatment regimen, including adherence to the medication regimen and
time-sensitive therapeutic lab draws.
Ethical Considerations
HIPAA considerations required that all patient information was to be accessed through
the online portals that were only accessible at BAART Turk. No patient names or identifiers
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were used throughout this paper or in other documents that were seen and used outside of the
HCV treatment program at BAART. IRB approval was not indicated for this project since it did
not qualify as research. However, an SOD was completed because the project qualified as a
practice change model.
Of the six values that are known as the principles of the Jesuits, ‘women & men for and
with others’ (Creighton University, 2018) is reflected in this project. The focus of the project
exhibits the value of providing community outreach and enhancing care for the poor and
marginalized groups by encouraging ‘care for the individual person’ (Creighton University,
2018). As discussed earlier in the theoretical framework of the EBM, an individualized approach
to patient care can promote adherence to and overall success in patient health outcomes.
The seventh provision of the ANA Code of Ethics is demonstrated in this project, which
states “the nurse, in all roles and settings, advances the profession through research and scholarly
inquiry, professional standards development, and the generation of both nursing and health
policy” (American Nurses Association, 2015). Research and scholarly inquiry has allowed the
DNP author to identify the need for a HCV treatment program for the high-risk patient
population seen at BAART Turk, and has helped initiate a HCV treatment policy for the patients
in the BAART Turk setting.
SECTION III: Methods
Specific Aims
The overall goal of the project is the reduction of HCV infection among positive patient
population in SF at one community-based clinic as a model for a larger scale community-based
treatment protocol across all BAART clinics. The specific target population was patients at
BAART Turk who were living with active HCV and were mostly PWID. The implementation of
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a HCV treatment program at BAART Turk was important because many of the patients that are
seen there are high-risk for HCV, and screening, diagnosing, and treating are effective in this
specific patient population.
The aim of the project was to have at least 80% of the identified hepatitis C virus (HCV)
positive patients at BAART Turk Clinic enrolled and successfully complete treatment with the
antiviral medication Mavyret by December 2019. Appropriate measures to document success
were based on patient participation, toleration and use of Mavyret and SVR at 12 weeks.
Objectives
The primary objectives of this project were: a) to decrease rates of HCV infection using
effective drug therapy, b) educate the patient population who was at high-risk for infection, and
c) to prevent reinfection through education. According to Manns et al. (2017), as long as there is
no availability of prophylactic vaccines for HCV, the treatment and control of the virus must be
through prevention strategies (ie: sterile medical equipment in developing countries, no re-use of
needles while using drugs), effective screening programs, and access to treatment for all. This
project will use the following goals to guide successful implementation.
a) To educate 100% of the providers at BAART Turk on HCV and increase knowledge of
HCV infection, including screening, assessment and treatment protocols by completing a
post seminar survey with improved scores compared to the pre-education survey.
b) To design and implement an 8-week HCV treatment program utilizing the medication
Mavyret for BAART Turk patients.
c) To achieve 100% uptake and success of the HCV treatment program at BAART Turk
by all eligible HCV positive patients, as demonstrated by an attained SVR at 12 weeks.
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d) To achieve 85% staff satisfaction with the implementation of the project at BAART
Turk.
e) To achieve an overall 85% patient satisfaction with project effectiveness and
implementation.
The collaboration and development of a HCV treatment program at BAART Turk Clinic
was designed to create a low barrier, easy to treat workflow with San Francisco Health Plan
(SFHP) that allowed easy approval and execution of treatment options for patients at BAART
Turk Clinic.
Interventions
Developmental Phase
During the developmental phase of the project, focus was given on using the gathered
data and evidence to create the educational materials for staff, providers, and patients. A
PowerPoint was created by the DNP author for the counselors at this clinic to educate on what
HCV is, the importance of HCV being treated, and how they as counselors could help support
their clients in receiving care and being treated and cured from HCV. Along with the
PowerPoint, educational pamphlets and flyers about HCV created by End Hep C SF were used as
reference for the counselors.
The second phase of development involved creating the clinic algorithm for treatment
(Appendix N). This included working with the medical director, lead physician, the lead NP, and
the DNP author in designing a process for screening at risk patients, deeming them eligible, and
recruiting them into a cohort model for treatment. The cohort design was selected, to ensure a
more streamlined process of tracking and monitoring the patients as an introductory model.
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The selection and preparation of the first cohort involved completing chart reviews to
determine the eligibility of patients. The eligibility criteria were: the patient had to have active
insurance through the SFHP, the patient could not be co-infected with active hepatitis B or HIV,
the patient had to have confirmed HCV based on blood test results, and have no evidence of a
compromised liver (liver cirrhosis). A total of several hundred chart reviews were done, and by
way of using mail, phone calls and clinic visits six patients were recruited into the first cohort. It
was important to conduct chart reviews to see which patients did and did not have an assigned
primary care provider (PCP), which patients were due for a HCV screening, and which patients
were active with BAART Turk, but have not seen a PCP for a considerable amount of time (one
year or over) and were discovered to be HCV positive the last time they were seen. These
patients were sent letters in the mail to help initiate the process of receiving HCV education and
treatment. In order to efficiently follow all of this information, an excel spreadsheet was created
to keep track of these patients.
A relationship between USBioServices and the clinic was established since the clinic was
receiving the medication Mavyret from this pharmaceutical distributor. A conference call
establishing a profile for the medical director, staff nurse practitioner, lead nurse, staff physician,
and DNP author of the clinic was done so medications could be ordered for the HCV patients.
The DNP author met with the dean of the college of nursing of the University of San
Francisco (USF) to propose the project idea and the goals and objectives, and to create a
timeline.
Educational Phase
The educational sessions were the next step in the process. The DNP student led the
educational sessions to the counselors, staff, and providers via PowerPoint presentation at the
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site over a 1-hour period during their lunch break. Snacks and 25 print-outs of the PowerPoint
slides (each packet being 10 pages) were printed for a total of 25 attendees. Immediately
following the educational session, the knowledge attained and the teaching effectiveness of the
DNP author was assessed by administering pre- and post-education surveys distributed to the
counselors who would be working directly with the patients. Following the staff education phase,
education was provided to the patients who were infected with HCV via the lead NP, lead
physician, and medical director during medical appointments. Patient education about HCV was
provided verbally during individual clinic visits (and reinforced at subsequent clinic visits) by
the provider and by distribution of handouts given to the patient directly from the provider. The
main points addressed were side effects of the medication and the importance of treatment
adherence.
Implementation Phase
The algorithm created for the HCV treatment program (Appendix N) at BAART Turk
helped identify patients that were qualified to receive HCV treatment. Patients were selected for
blood lab work-up of HCV by determining if they were high-risk (IVDA, homeless, history of
other forms of substance abuse). After this was done, the identified patients were notified via inperson appointments with one of the providers involved with the project that they were
categorized as being high-risk for HCV, and that blood work was ordered to test for the presence
of HCV. If the blood work came back as the patient being HCV positive the patient was made
aware of their positive HCV status during a follow-up blood work appointment with the
provider, and provided a pamphlet and verbally educated about what HCV is, notified that they
qualify for a HCV treatment program being established at the clinic. The provider then assessed
the patients interest in receiving treatment. If the patient agreed to treatment, further education
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was provided about next steps including: blood work that needs to be obtained during and after
treatment, the type of medication (Mavyret) they will be receiving and potential side effects
associated with said medicine, DOT vs take-home therapy, frequency of taking the medicine,
future check-ins with the provider, and other resources and references regarding HCV. After the
patient received education about HCV and expressed interest in receiving treatment, a written
consent was signed by the patient and kept in their patient profile chart at the clinic. The DNP
author took into consideration all the information that was obtained from the patients,
counselors, and staff at the clinic to establish the most effective, efficient, and clinically and
financially feasible HCV treatment program possible.
To ensure the safety of patients, the patient’s liver panel had to show no signs of a
decompensated or compromised liver to qualify for treatment at BAART Turk. If the blood work
showed signs of an inadequate liver function the patient was referred to the liver clinic at
University of California San Francisco (UCSF) for further evaluation. If the patient was cleared
to receive HCV treatment based on the results of the work-up done at USCF, their treatment was
initiated and managed by UCSF so that closer monitoring of the patient’s liver enzymes could be
done.
Initially 20 patients were identified as being high-risk for HCV and were ordered to have
blood work done. After the blood work was reviewed, a total of six patients qualified for and
were recruited for HCV treatment. It was decided that a cohort model be followed to proceed
with treatment of the identified patients for the ease of monitoring by providers. Consents to
receiving treatment and obtaining blood work at 4-weeks into treatment (liver panel, viral load),
8-weeks at treatment completion (liver panel, viral load, SVR), and 12-weeks after treatment
completion to screen for SVR were signed by each of the six patients in the cohort. The lead NP
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was responsible for the review and monitoring of blood work throughout the course of each
patient’s treatment.
Each of the six patients in the cohort had six visits during their HCV treatment. The first
visit consisted of the provider performing an in-person evaluation and ordering blood work to be
done. The labs ordered were: complete blood count with differential (CBC with diff), complete
metabolic panel (CMP), PT/INR, Hep C viral RNA genotype, Hep A antibody, total Hep B core
antibody, total Hep B surface antigen with reflex, Hep B surface antibody, and HIV fourth
generation. After the labs were processed and confirmed that the patient was HCV positive, the
provider reviewed the labs with the patient and educated them about HCV, consequences if left
untreated, and that there is a HCV treatment program now being offered at BAART Turk that is
free of charge to them. Other topics discussed were possible side effects of the medication
Mavyret and the importance of treatment adherence. Gaining patient consent to participate in the
program was the final step of the initial visit.
The next visit was one week after the initial evaluation to start the medication. The first
dose was directly distributed from the provider to the patient, and for the remainder of their
treatment the patient was to receive their daily dose of medication from the dispensing nurse via
DOT. A follow-up appointment one week after the first week of administration of the medication
was scheduled with the provider to assess for medication side effects and treatment adherence.
At four weeks into treatment blood work was done which consisted of: CMP, a HCV viral load
(HCV VL), and a core antibody HBC viral DNA if the patient was HBV positive upon
evaluation. At eight weeks, a HCV VL was drawn, and then 12-weeks after treatment completion
a SVR 12 was drawn to determine a cure from HCV.
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Table 2
Visit Number and Content of Each Visit
Visit
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medication
and its
possible
side effects,
and
importance
of adhering
to treatment
and routine
follow-up
visits.
-Obtaining
written
patient
consent to
start
treatment

Table 2
The DNP author kept track of the patients receiving HCV treatment using an Excel
spreadsheet. The course of Mavyret was either 8 or 12 weeks (depending on the grade of liver
cirrhosis of the patient), and blood work to detect the presence of a viral load was drawn at 4, 8,
and 12 weeks, and again 12 weeks after treatment completion to see if they had attained a
sustained virologic response, also called an SVR12. The lab values during and after treatment
helped the clinic determine the effectiveness of the establishment of the HCV treatment program
and what was working well and what changes needed to be made.
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GANTT
A Gantt chart was created to provide a schedule to help plan, coordinate, assign, and
track specific tasks required for the project (Appendix I). The Gantt outlines the development,
implementation, and evaluation timeline for the project. The project spanned 10 months.
Initiation of the project began with meeting with the stakeholders of the project, and then
acquiring knowledge about the topic of the project (HCV) through online modules, connecting
and meeting with expert panels on HCV, and having lectures with the staff MD of the clinic.
After this part was completed, a teaching was provided by the DNP author to the counselors
about HVC. During the time of the counselor teaching, the DNP author and the stakeholders
established a relationship with USBioServices to set up a profile for ordering the Mavyret. The
roll out date of the project was in September 2018. Blood work of the patients was obtained prior
to the start of treatment, during treatment at 4 and 8 weeks, and then 12 weeks after the
completion of treatment. Data collection via the use of Excel and Practice Fusion at the clinic
were utilized to organize findings and results.
SWOT Analysis
A Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis was performed to
identify what could impact the forward progression of the HCV treatment program at the clinic
(Appendix F). It allowed the DNP author to focus on the strengths of the project to minimize
threats and to use opportunities to the best advantage.
One of the major strengths of the project was its ability to address the healthcare gap seen
in San Francisco regarding the lack of access for high risk patients to receiving HCV treatment
and cure from disease in their primary care setting. Other proposed strengths were: the use of
medication that was proven to have little to no side effects (so it was easily tolerated by patients),
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the distribution of the HCV medications via DOT (which promoted patient adherence to the
medication regimen), and frequent contact between the lead NP, lead physician, and medical
director with the patients during primary care appointments and when the patient came in for
their DOT. Another strength of the project is the grant that was awarded to BAART Turk from
the SFHP to create and implement a HCV treatment program. The establishment of the program
promoted and provided low barrier access to HCV treatment among high-risk, hard to reach
patient populations (IV drug users, homeless). Another strength lies in the reduction of
transmission of HCV among high-risk patient populations.
The key weakness identified in this project was determining how to improve access to
receiving HCV treatment. Other weaknesses were related to factors associated with patient
compliance: obtaining timely and protocol driven blood work from patients to determine the
status of their HCV and if any liver cirrhosis was present, the possibility of missing follow-up
visits with PCP due to lack of transportation which created a lack of adherence to the medication
regimen. The patient demographics (they were homeless and did not have an address or phone
number to get into contact with) also created a barrier to medication adherence. Lastly, there
were no patient incentives in the budget to encourage the patients to have their blood work
drawn, attend follow-up appointments, or continue with the medication regimen, apart from the
proposed idea of HCV cure.
The major opportunity that was presented by this project was the community outreach to
HCV patients who had few treatment options toward a cure of HCV infection. Other
opportunities were: the rate of HCV and the comorbidities associated with it would bring
healthcare costs in San Francisco down, awareness of prevention and reinfection prevention
methods were taught to the community, and chronic HCV initiatives were established at the
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clinic. These opportunities create another place in the community where HCV patients can be
treated, in turn improving access for this patient population.
The threats identified were: homeless patients were unable to be tracked/contacted,
unable to identify all potentially qualifying patients due to discrepancies within the charting
system, the medication shipment from USBioServices did not come in time or there was an issue
with the delivery, the patient dropped out of being treated for HCV due to side effects or
personal reasons, the patient moved away, the patient expired, the patient was no longer a
methadone patient and did not want to come back to this clinic, and quality improvement
projects were being rolled out at the time of the project which posed as a barrier to progressing
forward.
Time and Cost Summary
The direct costs (Appendix G) were split into three categories which were ‘staffing’,
‘training’, and ‘travel’, and were based off a 52-week (one year) budget. The budget calculated
for ‘staffing’ was based on the salaries and time of the DNP author, the project oversite (a
physician), and the consulting public health physician. The budget calculated for ‘training’
consisted of the salary and time of the counselors, the site nurse practitioner support, and the
supplies and resources used for the counselor training (printing of PowerPoint slides, pens, and
refreshments). The budget calculated for ‘travel’ included mileage based off the IRS standard
mileage rate (IRS, 2017), bridge tolls, and parking. The overall cost to implement this project at
BAART Turk for six patients totaled $106, 473.27, which was covered by the grant from SFHP.
The medication Mavyret was covered by the grant distributed by SFHP to initiate the HCV
treatment program at BAART Turk, so this was not calculated into direct expenses.
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According to End Hep C SF (2017), there are a total of 12,000 people in SF living with
active HCV, and the median ages at death for people living with active HCV is 60 years,
respectively (Carter, 2014). Based on an analysis done by Razavi et al. (2013), the total lifetime
healthcare costs of individuals in the U.S. with advanced liver disease due to HCV is $6.5 billion
per year, and the lifetime cost of an individual living with HCV is estimated to be $64,490
annually. The calculated ROI is 27.2 indicating that the project, through treatment with Mavyret,
reduces the cost of successful treatment to 27.2% of the average cost of treatment over a
patient’s lifetime. This supports the premise that HCV treatment in the SF patient population will
greatly decrease healthcare costs associated with this disease, and overall positively benefit the
healthcare system.
Grant/Projected Costs
Through the SFHP the BAART Turk HCV Grant, a total of $60,000 will be funded
annually to the clinic over a total of three years (September 2017 to September 2020) to cover
staffing ($53,000), equipment ($2,000), and other anticipated costs ($5,000), which will
accumulate to a total of $180,000 by September 2020. The clinic’s target was to start out by
treating 20 patients in the first cohort, and then eventually treat hundreds of high-risk patients by
September 2018.
Approximately 20,000 patients die each year from HCV-related liver disease, which in
2013 surpassed the total number of deaths from 60 other diseases reported to the CDC. Some of
these diseases include, tuberculosis, HIV, and pneumococcal disease (Alkhouri, Lawitz &
Poordad (2017). According to Dartmouth Medical School (2018), more than 80% of HCV
patients will develop chronic liver disease, 15-20% will develop cirrhosis in a 5-year period, and
25% may have cirrhosis by 10-20 years. Hepatitis C is responsible for one-third of all liver
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transplants, and the cost of liver transplants for HCV alone costs the US healthcare system nearly
$300 million annually. The average lifetime costs of HCV without liver transplant costs about
$100,000 for each patient yearly. If 80% of the 4.5 million actively infected HCV patients
develop chronic liver disease, the total lifetime cost for this group is around $360 billion dollars.
And if the estimated survival of these patients is 40 years, the annual healthcare cost for the US
population with chronic HCV is estimated to be as high as 9 million dollars (Dartmouth Medical
School, 2018). With these staggering numbers, it is apparent that the US has a serious issue it
needs to face when it comes to treating this patient population to lower healthcare costs
(Appendix G). According to Alkhouri, Lawitz & Poordad (2017), recently approved regimens
have helped close gaps in access to healthcare, and almost all HCV-infected patients can be
cured. Future research is needed to develop a preventive vaccine, eliminate the risk of vertical
transmission from mother-to-child, and to decrease the number of acute HCV infection cases.
Work Breakdown Structure/Stakeholders
A work breakdown structure was created by the DNP author (Appendix D) to provide an
outline of the key deliverables of the project that were to be executed by the project team. The
ultimate focus was to establish a HCV treatment program at BAART Turk Clinic. The first phase
was to establish a relationship with the stakeholders, who were the medical director of BAART
Turk, the lead physician, the lead NP, and the counselors of the patients. Phase two was for the
DNP author and the lead NP at BAART to attain knowledge of HCV and meet with the
appropriate HCV experts. Next was to provide an education training session to the counselors of
the patients. Phase three consisted of developing a plan to move forward with the
implementation of the project. Phase four was the actual carrying out and launching of the
project.
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Information Flow
A communication flow chart addressed the type of information that was communicated,
who it was communicated to and with, how often it was communicated, and the method of
communication that was used (Appendix H). The communication happened between the DNP
chair, DNP committee, and the on-site staff NP, MD, and the medical director via email, inperson, and phone. Important matters were discussed were: project coordination and planning,
the status of the project, changes in the project methods, reports of milestones, and variances. It
was important to know what communication paths to follow to promote efficient and effective
communication which allowed more organization.
Study of the Interventions
The DNP author analyzed the results of the three identified measures (see Section III:
Objectives, page 23) in various ways. The knowledge of the counselors was assessed by
comparing the in-person pre- and post-test survey results. The test consisted of a total of nine
multiple choice questions (Appendix E). The same test was distributed before and after the
teaching. The successful implementation of the protocol was assessed by the number of patients
who were recruited and started treatment. Next, the number of patients who completed treatment
were evaluated, which was all six patients who were recruited and started. Along with treatment
completion, attained SVR was also evaluated through blood work. All six of the patients attained
SVR indicating a cure from HCV.
Staff satisfaction of project implementation was evaluated through a personal survey and
reflection of the project. Staff satisfaction surveys were created by the DNP author on
SurveyMonkey and distributed to the five staff directly involved with the program via email. All
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five of the staff completed the survey. There was a total of three questions on a Lichert scale that
produced qualitative data (Appendix J).
After the completion of treatment, in-person patient satisfaction surveys were
administered to the six patients who completed treatment during their provider follow-up visits.
The survey consisted of a total of six questions including important topics, like medication side
effects and if they would recommend the program to future patients. Five of the questions were
on a Lichert scale that produced qualitative data, and one questions was ‘yes’ or ‘no’ (Appendix
K).
Measures
The five identified outcome measures for this project were:
1. 90% of the participating providers at BAART will increase their knowledge related
to HCV screening, assessment, treatment as evidenced by pre- and post-test surveys
indicating scores of 90% and above. There will be a total of 9 questions asked and
will demonstrate knowledge about HCV treatment protocols and side effects.
2. Ten BAART patients will be identified, screened, assessed, and started on HCV
treatment with Mavyret based on the identified and initiated HCV treatment protocol
at BAART Turk.
3. At least 50% of selected patients who received treatment for HCV will complete
their medication course of Mavyret and have an attained SVR12.
4. 85% of the providers will express satisfaction with the design and implementation of
the HCV treatment program.
5. 85% of the patients treated will express satisfaction with the overall effectiveness
and implementation of the treatment program.
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Analysis
With regard to provider education the targeted outcome was that 90% of participating
providers would increase their knowledge related to HCV screening, assessment and treatment.
Actual results demonstrated that 100% of providers increased their knowledge as defined above.
I believe this is attributable to effective teaching methods, provider enthusiasm for the program,
and 100% provider participation in the educational session.
With regard to the design and implementation of the HCV treatment program, the
original target was to identify and serve 10 BAART Turk patients with Mavyret. Actual results
included treatment of only six HCV positive patients, all of whom successfully completed the
HCV treatment program and demonstrated attained SVR12. Fewer patients were eligible for
treatment due to the presence of compromised liver function in otherwise eligible patients.
With regard to completion of treatment, the targeted outcome was 50% of selected
patients would successfully complete treatment and demonstrate attained SVR12. Actual results
demonstrated a 100% completion rate of all patients selected and enrolled in the program., and
an attained SVR12. Success was attributed to frequent provider contact and low side effect
profile of the medication.
With regard to the rate of provider satisfaction with the design and implementation of the
program, the target was 85%. Actual results demonstrated 98% rate of satisfaction. The high
satisfaction rate was attributed to the efficiency of the program design and delivery, and
coverage of costs by funding from the grant.
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With regard to patient satisfaction with program effectiveness and implementation, the
original target was 85%. Actual results demonstrated 98% patient satisfaction rate, attributable to
frequent provider contact and a strong patient support network within the healthcare setting.
Throughout this project, data was collected, organized, and analyzed in an Excel
spreadsheet and analyzed using Excel tools, including bar graphs, yields, and descriptive analysis
that was accessible to the DNP author and the appropriate stakeholders. Each intervention was
analyzed and assessed using one or several of the above identified methods. Both qualitative and
quantitative data were collected.
Evaluation
The cohort consisted of a total of six patients who were enrolled in and completed
treatment in the HCV treatment program. A total of four staff were directly involved with the
implementation of the program, which included the lead nurse, medical director of BAART
Turk, lead physician, and lead NP.
Only the results of patients who had completed the entire course of treatment of Mavyret,
and had completed all the required blood work before, during, and after treatment were assessed
and analyzed. An SVR12 was attained by all patients diagnosed with HCV 12-weeks after
treatment completion of Mavyret. A successful treatment outcome was an SVR12 where the
HCV was undetectable for 12-weeks after the completion of treatment, indicating a cure from
HCV (Porter, 2015).
The DNP author evaluated the results of the five identified objectives in various ways.
With regard to provider education, materials that included in-person presentations, distribution of
pamphlets and other printed education materials were provided. Provider knowledge was
assessed by the creation and distribution of a printed post-teaching survey by the project leader.
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Based on the results of the survey after they were physically collected and analyzed by the DNP
author, the provider teaching was 100% effective.
In regard to the design and implementation of the HCV treatment program, there was
completion of an electronic and printed algorithm that presented the layout and workflow of the
HCV treatment program at BAART Turk. After several revisions of the work flow program
structure, a final revision was achieved and was 100% effective in guiding providers through the
HCV treatment program initiation, monitoring and evaluation of the identified HCV patients.
This was evidenced by the unobstructed flow of patient progression through the program from
start of taking the medication to ending with obtaining the SVR12, 12 weeks after treatment
completion.
With regard to completion treatment, data was collected and analyzed based on the
completion rates of the patients at BAART Turk who were treated for HCV. Once a patient had
completed their HCV treatment regimen and had their blood drawn to determine the presence of
an SVR 12, 12 weeks after treatment completion, it was determined that the HCV treatment
program was successful and that the patient was cured from HCV. Out of the six patients who
qualified for the HCV treatment program at BAART Turk, all six completed treatment, resulting
in 100% efficacy and effectiveness of the program.
With regard to provider satisfaction, data from the obtained surveys showed that there
was a high satisfaction rate based on the 98% achieved rate. The DNP author believes this is
primarily attributable to the funding from the grant, and shows that grants are an efficient and
effective way to initiate programs at clinics.
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With regard to patient satisfaction, data from the obtained surveys showed there was a
high satisfaction rate of 98%. The DNP author believes this is attributable to the frequent
provider contact.
SECTION IV: Results
Overall, the implementation of the HCV treatment protocol at BAART Turk proved to be
highly successful. Of the desired 20 enrolled patients, 6 were enrolled, remained compliant, and
completed treatment with an attained SVR at 12 weeks. Staff and providers expressed a positive
attitude towards the knowledge gained, and felt that the protocol was feasible and well driven.
Provider Knowledge
A total of 25 counselors were at the counselor training session conducted by the DNP
author. The same pre- and post-test survey were distributed in-person to the counselors before
and after the training to assess their knowledge on the topic of HCV. Survey results were directly
collected in-person and analyzed by the DNP author. There was a score of 80% understanding of
HCV before the teaching and a score of 100% after the teaching.
Patient Satisfaction
A total of six patients started and completed treatment and attained an SVR12. Based on
the results of the anonymous patient satisfaction survey there was an overall very high patient
satisfaction rate (99%). With the exception of one patient who scored a ‘4/5’ regarding the
survey question ‘how satisfied were you with the medication itself?’, to which he/she answered
that patients need to be informed of the potential weight gain from the medication, the other
survey questions scored by this patient, and all the other patients, registered a score of ‘5/5’ on a
total of six questions.
Staff Satisfaction
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The results of the ‘BAART staff satisfaction survey’ (Appendix J), which was created
and distributed by the DNP author through a SurveyMonkey, reflected a high staff satisfaction
rate (98%). A total of five staff who were directly involved with the HCV treatment program
consisted of three medication dispensing nurses and two providers. The total involved staff
completed the survey. The survey consisted of a total of three questions, and all who took the
survey rated their experience with the HCV treatment program as ‘highly likely’ or ‘likely’ that
the HCV treatment program is sustainable, and that the program contributed to overall
improvement of HCV patient outcomes. The last survey question was an open-ended answer that
asked about any improvements and/or changes that could be made to the current HCV treatment
program model at BAART that could make it better. One individual skipped the question and
did not answer, but the other 4 answered. One response was to have someone from quality
improvement focus on the project. Another was for BAART to be provided resources to enhance
patient compliance with check-ups and provider visits (ie: a gift card incentive, bus or taxi
voucher for transport to the outpatient liver clinic). One individual stated it would be appreciated
if the providers clearly explain to the patients that they need to take all 3 pills of the HCV
antiviral Mavyret at the time of dosing in front of the dispensing nurse. Apparently, patients were
under the impression that they could take the Mavyret home with them and dose it themselves.
The final shared thought was the dispensing staff would appreciate to be updated of the treatment
results of patients (ie: attained SVR12) since they have no way of knowing if the treatment was
successful or not, and if the patient is cured from HCV. All the responses are valid and provide
excellent feedback on how the HCV treatment program can be improved from the medical
provider standpoint.
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The results of the patient and staff satisfaction surveys are indicative and supportive of
the fact that HCV treatment is sustainable and feasible in the PWID population, and that other
clinics interested in establishing and implementing a HCV treatment program into their setting
should be encouraged and confident in doing so.
HCV Cure Rate
Of the six patients who started and finished their HCV treatment, six completed treatment
and 100% achieved SVR, indicating a cure from HCV.
Barriers to Implementation
There were many barriers that were encountered in this project. The first was screening
and identification of patients which were discovered during patient chart reviews. It was
discovered that the monthly generated patient list from SFHP were not accurate, which prevented
the clinic from determining who was an active patient and might qualify for treatment versus
someone who was inactive, assigned to a different clinic, or had established themselves at a
different clinic and therefore was disqualified from treatment at this clinic.
There were some patients who were assigned to Anthem Blue Cross and Medi-Cal, and
these do not generate monthly lists, so it was challenging to determine if patients were active
with their insurance and receiving healthcare or not. In this same group, some patients were
unaware that they were assigned to this clinic and ended up establishing their care at a different
clinic. It took a substantial amount of time to figure this out after spending a lot of time and
effort investigating and tracking down patients and where they were receiving care.
Another issue was the clinic was rolling out a quality improvement (QI) program that
interfered with the progression of the project. The time and resources that were being used
towards the HCV treatment program were put to a halt until the QI project was completed.
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While multiple stakeholders were working as a collaborative team and conducting patient
chart reviews, it was very important to create a key/legend to avoid confusion. This is not done
originally, so work that had already been done was done again, and in turn this created
inefficiency and loss of progression of the project.
The second issue was patients were not motivated to initiate or adhere to their treatment
regimen. This included: not coming to follow-up appointments, not having time-sensitive blood
drawn at Quest Diagnostics or at the clinic, not adhering to the medication regimen via DOT
(direct observational therapy) or take-home, and/or the patient was a past methadone patient and
did not want to return to this clinic for personal reasons. The budget for the HCV treatment
program did not include incentives for the patients, like gift cards to Target, Safeway, or CVS,
which would have tremendously helped with adherence to the HCV treatment. Patient incentives
would have been very helpful since previous clinics who have established HCV treatment
programs had incentives in their budget and said it was highly effective.
It was challenging to determine if the patient had, had labs drawn or not, and which lab
values were the most recent. For example, the San Francisco Department of Public Health
(SFDPH) and the patient care system used at the clinic were on different databases and did not
share information. The patient occasionally had HCV labs drawn at a hospital, but since the two
systems between SFDPH and the clinic did not communicate, it was impossible to determine
when and if labs were drawn, and it would take time and effort to have access to these records
(obtaining a release of information (ROI) from the hospital).
Another issue was the medication shipment would occasionally arrive late or the
shipment would not come at all. Two-weeks’ worth of Mavyret was sent in each shipment for
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each patient. It was learned to avoid failure of mediation delivery and receipt by making sure the
request for the medication was put in as early as possible.
Wirfs (2018) states the hepatitis B virus (HBV) could become reactivated during or after
treatment with Mavyret. It was important to test all patients for HBV infection by measuring the
HBsAg and anti-HBc prior to initiating therapy with Mavyret (Wirfs, 2018). After this was
checked, it was wise and beneficial for the patient to receive both an HAV and HBV vaccine.
Unfortunately, pharmacies like CVS and Walgreens, do not carry either vaccine unless ordered
specifically for a patient. The DPH grant at the clinic covered only HAV vaccine, not HBV. This
was another barrier that interfered with treatment adherence.
Lack of insurance to cover Mavyret, which in turn limited patient access to receiving and
adhering to the treatment regimen, interfered with treatment progression. For example, Medicare
did not cover Mavyret, it only covered Harvoni. Other factors that limited patient access were the
patient did not have a car, did not have money for bus fare, lived too far to walk to appointments,
or other issues that impeded their access, such as being homeless.
Limitations
The limitations identified include some patients being ineligible for initiation of HCV
treatment at BAART due to the status of their liver function; shipments of the HCV medication
would sometimes not be delivered on time resulting in failure of dosing the patient on the desired
day and time; patients did not have access to transportation to attend appointments for dosing of
the HCV medication, to follow-up with the provider, have labs drawn, which overall resulted in
delay of treatment; and there were times when the patient was not able to make it to BAART
Turk during their open hours to have labs drawn, so they would have to go to a different clinic
that was less convenient to travel to.
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Based on the identified limitations discovered during the creation, implementation,
results and findings of this project, it is recommended that patient incentives (i.e., gift cards, taxi
vouchers, bus passes) to enhance and encourage treatment adherence (i.e., to have labs drawn,
dosing of HCV medication) be included in the project budget, and that a back-up supply of the
HCV medication be available in case a delivery does not come on time. In the absence of an
existing HCV treatment protocol, the project HCV treatment guidelines were created at BAART
Turk, and they excluded patients who had poor liver function. Hopefully as HCV treatment
advances, future patients who do have decompensated liver function will be eligible for the
immediate initiation of HCV treatment at BAART.
SECTION V: Discussion
Summary
Of the key findings in this project, the major one identified was the fact that high-risk
patients, particularly ones who are PWID, can be effectively treated and cured of HCV. The
number of PWID who are assessed and treated for HCV is increasing and it is important that
access be provided for this patient population because maximizing treatment for PWID can be an
effective preventative measure for decreasing transmission and mortality associated with long
term consequences of HCV. Reflecting back on the available literary evidence and positive
outcomes of the project, it is evident that high-risk patient populations (PWID) who have HCV
can be effectively treated and cured of HCV, and that this patient group should not be excluded
from receiving treatment. The knowledge of the identified HCV positive patients was assessed
by verbal confirmation that they understood there was access to and availability of HCV
treatment at the clinic.
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Along with the 100% treatment adherence and the one patient who revealed in their
patient satisfaction survey that they had the undesirable side effect of weight gain, the majority
of the patients were highly satisfied with the treatment program and their personal experiences,
despite some of the challenges, such as lack of transportation and incentives and inconvenient
clinic hours. The project effectively demonstrated that HCV treatment for high-risk patient
populations can be truly successful and allow them to achieve cure as defined by attained SVR,
and additionally, this project overcame many of the previously identified obstacles to successful
HCV treatment, including difficulty with treatment adherence due to lack of patient education
and knowledge, significant side effects, and lack of access to HCV treatment programs in
geographic areas prone to high risk of infection.
Based on the results and findings of the patient and staff survey results, and the 100%
outcome of completion of HCV treatment and attained SVR, it can be confidently recommended
that the creation and implementation of HCV treatment programs in clinics that are primary care
homes for high-risk patient populations is highly feasible, efficacious and can be successful.
Conclusion
It is widely known that there is a lack of access to and availability of HCV treatment for
high-risk populations in the San Francisco community. The implementation of the HCV
treatment program at this clinic will continue to be very beneficial by reducing healthcare costs
associated with HCV and its comorbidities in San Francisco. The program can also serve as a
model for other clinics in the Bay Area for effective treatment of HCV. The project demonstrates
the successful establishment of a HCV treatment protocol that is sustainable, progressive, and is
clearly efficacious in the care and treatment of HCV in this high-risk population, leading to a
decreased burden to society and overall healthcare expenditures.
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SECTION VI: Other Information
Funding
Besides the BAART Turk HCV Grant funding supplied by the SFHP, there was no other
identified need for outside funding for this project. The DNP author did not receive any
compensation for time spent traveling, planning, implementing, or evaluating the project. There
were some minor out of pocket costs absorbed by the DNP author, which are reflected in the
budget overview.
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Appendix A: Statement of Non-Research Determination Form

DNP Statement of Non-Research Determination Form
Student Name:__Annie Pedlar___________________
Title of Project: HCV Treatment Program at BAART Turk Clinic
Brief Description of Project: Establishing and implementing a HCV treatment program
at BAART Turk Clinic in San Francisco, CA.
A) Aim Statement: The overall goal is to screen, assess, and treat HCV positive
patients at BAART, to decrease rates of HCV infection using effective drug
therapy, educating the patient population who is at high-risk for infection, and
preventing reinfection through education.
Objective 1: To educate 100% of the providers at BAART Turk on HCV and
increase knowledge of HCV infection, including screening, assessment and
treatment protocols by completing a post seminar survey with improved scores
compared to the pre-education survey.
Objective 2: To design and implement an 8-week HCV treatment program
utilizing the medication Mavyret for BAART Turk patients.
Objective 3: To achieve 100% uptake and success of the HCV treatment program
at BAART Turk by all eligible HCV positive patients, as demonstrated by an
attained SVR at 12 weeks.
Objective 4: To achieve 85% staff satisfaction with the implementation of the
project at BAART Turk.
Objective 5: To achieve an overall 85% patient satisfaction with project
effectiveness and implementation.
B) Description of Intervention:
1) Research to determine need for HCV treatment program in SF.
2) Perform patient chart reviews to see who is eligible and appropriate for
treatment.
3) Provide patient education to the patients and the patient’s counselors regarding
the HCV treatment program and what to expect (benefits of treatment, possible
side effects that may be experienced, resources for HCV information,
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prevention of reinfection, availability of provider support).
4) Oversee the initiation, constant monitoring during treatment, and the
completion of HCV treatment with proper blood work.
5) SVR12 determines if patient cured from HCV.
C) How will this intervention change practice? Currently, there is no established
HCV treatment program at BAART Turk. Treating these patients will positively
impact the BAART Turk clinic and the overall healthcare system in a tremendous way
by preventing and reducing health complications/comorbidities that may be associated
with damage to the body due to HCV.
D) Outcome measurements:
Outcome 1: 90% of the participating providers at BAART will increase their
knowledge related to HCV screening, assessment, treatment as evidenced by preand post-test surveys indicating scores of 90% and above. There will be a total of
9 questions asked and will demonstrate knowledge about HCV treatment
protocols and side effects.
Outcome 2: Ten BAART patients will be identified, screened, assessed, and
started on HCV treatment with Mavyret based on the identified and initiated
HCV treatment protocol at BAART Turk.
Outcome 3: At least 50% of selected patients who received treatment for HCV
will complete their medication course of Mavyret and have an attained SVR12.
Outcome 4: 85% of the providers will express satisfaction with the design and
implementation of the HCV treatment program.
Outcome 5: 85% of the patients treated will express satisfaction with the overall
effectiveness and implementation of the treatment program.

To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the
criteria outlined in federal guidelines will be used:
(http://answers.hhs.gov/ohrp/categories/1569)

X This project meets the guidelines for an Evidence-based Change in Practice Project as
outlined in the Project Checklist (attached). Student may proceed with implementation.

☐This project involves research with human subjects and must be submitted for IRB approval
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before project activity can commence.
Comments:
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST *

Instructions: Answer YES or NO to each of the following statements:
Project Title:
The aim of the project is to improve the process or delivery of care with
established/ accepted standards, or to implement evidence-based change. There is
no intention of using the data for research purposes.
The specific aim is to improve performance on a specific service or program and is
a part of usual care. ALL participants will receive standard of care.
The project is NOT designed to follow a research design, e.g., hypothesis testing
or group comparison, randomization, control groups, prospective comparison
groups, cross-sectional, case control). The project does NOT follow a protocol that
overrides clinical decision-making.
The project involves implementation of established and tested quality standards
and/or systematic monitoring, assessment or evaluation of the organization to
ensure that existing quality standards are being met. The project does NOT
develop paradigms or untested methods or new untested standards.
The project involves implementation of care practices and interventions that are
consensus-based or evidence-based. The project does NOT seek to test an
intervention that is beyond current science and experience.
The project is conducted by staff where the project will take place and involves
staff who are working at an agency that has an agreement with USF SONHP.
The project has NO funding from federal agencies or research-focused
organizations and is not receiving funding for implementation research.
The agency or clinical practice unit agrees that this is a project that will be
implemented to improve the process or delivery of care, i.e., not a personal
research project that is dependent upon the voluntary participation of colleagues,
students and/ or patients.
If there is an intent to, or possibility of publishing your work, you and supervising
faculty and the agency oversight committee are comfortable with the following
statement in your methods section: “This project was undertaken as an Evidencebased change of practice project at X hospital or agency and as such was not
formally supervised by the Institutional Review Board.”

YES

NO

X
X
X

X

X
X
X
X

X

ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an
Evidence-based activity that does NOT meet the definition of research. IRB review is not
required. Keep a copy of this checklist in your files. If the answer to ANY of these questions
is NO, you must submit for IRB approval.
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human
Research Committee, Partners Health System, Boston, MA.
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Appendix C: Gap Analysis

Current State
•High risk patient population
at BAART Turk for having
HCV
•No current HCV treatment
program at BAART Turk

Identified Gaps
•Patient misconception of
medication side effects
•Poor awareness/education
•Do not see need for
treatment since are
asymptomatic
•lack of medical coverage
•Patient non-adherence to
medicaton regimen
•Lack of access to
medication, such as no car,
no money for bus
•Inability to contact patients
because are homeless (no
phone number, no address)
•Fear of stigmatization

Future State
•Established HCV treatment
program at BAART
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Appendix D: Work Breakdown Structure

PHASE 1: Establish
relationship with
stakeholders
Meet with Deb, MD,
Brian, MD, and
Cara, NP, counselors
of patients

Establish HCV treatment
program at BAART Turk Clinic

PHASE
4:
Launch
Chart reviews; identify
which patients are HCV

PHASE
2:
Educate

PHASE 3:
Development

Cara and I to meet with HCV
experts, and people that are
part of established HCV
treatment programs

Develop a plan for
moving forward
with project
implementation

Education provided
to the counselors of
the patients via inperson presentation
and training

Contact identified patients
via: phone, in-person
during PCP appt, mailed
letter
Determine if patient
agrees to Rx. If yes, order
appropriate blood work
Order Mavyret from
US BioServices
Treat patient with
Mavyret for 8/12
weeks. Check viral
load (VL) at 4,8,12
weeks, SVR at 12
weeks
Pt education on
prevention of
reinfection, once SVR
attained

Running head: HCV OUTREACH TREATMENT PROGRAM
Appendix E: Pre- and Post-Test Survey for Counselor Educational Session

UNIVERSITY OF
SAN FRANCISCO
Hep C Pre- and Post-Evaluation
1) What is hepatitis C?
a. It is a bacterial infection of the liver
b. It is a viral infection of the liver
c. It is the same as Hepatitis A and B
d. It is the same as HIV
2) How do we confirm that someone is Hep C positive?
a. Sputum sample
b. Urine sample
c. Blood work
d. Skin biopsy
3) What is the most common ‘mode of transmission’ of Hep C?
a. Sexual intercourse
b. Breastfeeding
c. Needle sharing
d. Someone who is infected and coughs on someone else (droplet)
4) Here at BAART Turk, we will be treating clients living with Hep C with a medication
called Mavyret. How long does the medication regimen last?
a. 3 weeks
b. 3 months
c. 8-12 weeks
d. 12-16 weeks
5) What are common side effects of Mavyret (select all that apply)?
a. Headache
b. Nausea
c. Dry cough
d. Fatigue
e. Constipation
f. Diarrhea
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Appendix E: Pre- and Post-Test Survey for Counselor Educational Session (cont.)
6) To determine if Hep C has been cured after the completion of treatment, we do a blood
test to check if there is a ___?
a. Hep C Antibody (Ab)
b. Hep B Ab
c. Sustained Virologic Response (SVR)
d. White blood cell count
7) How can clients receive their Hep C medication (select all that apply)?
a. DOT or window dosing
b. Through an outside pharmacy
c. It can be delivered directly to the client’s residence
d. Take-home
8) Which BAART Turk patients will we treat for Hep C?
a. All patients who test positive for Hep C
b. Patients who have a primary care provider outside of BAART Turk
c. Patients who do not have a primary care provider
d. Patients who have a primary care provider at BAART Turk
9) What are complications of untreated Hep C (select all that apply)?
a. Diabetes
b. Liver cancer
c. Ascites
d. Liver failure
e. Obesity
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Appendix F: SWOT Analysis

•

•
•
•

•
•
•
•
•

STRENGTHS
Good cause- brings awareness and
highlights the healthcare gap seen
in San Francisco regarding the
lack of access for high risk
patients to receiving HCV
treatment in the primary care
setting.
Mavyret has few to no SE (should
be tolerated well by all pt’s)
Window dosing (DOT very
beneficial)
Staff NP, staff MD, and medical
director have direct contact with
patients during PCP visits

OPPORTUNITIES
Out-reach to the HCV community
who have limited or no access to
healthcare
Reduction in liver disease in SF
Reduction in HCV rates by curing
Awareness of HCV in community
(prevention methods)
Establish chronic disease
initiatives at BAART Turk

•
•
•

•
•
•
•

WEAKNESSES
Identifying the insurance of each
pt
Identifying patients who are
HCV+ and VL+
Obtaining blood work from
patients (hard stick, not going to
Quest, arriving at BAART too late
in day and blood cannot be drawn
by RN)
Lack of transportation to PCP
visits and to have labs drawn
Pt demographics (homeless, no
phone number or address)
Adherence to Rx
No incentives in budget

THREATS (things that cannot be
controlled)
• Homeless patients are unable to
be contacted.
• Not identifying all possible
patients
• Only SFHP creates monthly list of
active patients…Anthem Blue
Cross Medical and Medical do not
generate such lists. How are we to
contact these patients who may be
eligible for Rx?
• Medication does not come in time,
difficulty in having meds received
• Patient drops out of Rx due to SE,
personal reasons
• Pt moves away
• Pt expires
• Pt is no longer receiving
methadone and does not want to
return to BAART
• QI panel management rolled out
at BAART
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Appendix G: Budget and Impact Analysis
Description
STAFFING
Project management
Project Oversite
Consulting Physician
TOTAL STAFFING
TRAINING
Counselor
Participants
Site NP Support
Printing
Pens
Refreshments
TOTAL TRAINING
TRAVEL
Mileage
Tolls
Parking
TOTAL TRAVEL
TOTAL PROJECT
BUDGET

Amounts/Calculation
= $65/hour x 135 hours
= $120/hour x 10
hours/week
= $120/hour x 5 hours/week

= $30/hour x 30 people x 1
hour
= $80/hour x 9 hours
In kind from BAART
$2 per box (x 1 box)
$20 (baked goods)

40.8 miles/week x IRS rate
54.5 cents
$7/week x 52 weeks
$18/day x 52 weeks

Total
$8,775.00
$62,400.00
$31,200.00
$102,375.00

$900.00
$720.00
$0.00
$2.00
$20.00
$1,642.00

$1,156.27
$364.00
$936.00
$2,456.27
$106,473.27
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Cost to US Healthcare System of HCV Infection
Annual Cost of Advanced Liver
Disease Caused By HCV
Average Lifetime Cost Per Individual
Infected With HCV
Estimated Number of Individuals with
HCV in SF
Estimated Lifetime Cost of HCV in SF

$6.5 billion
$64,490
12,000
$774 million

Returns on Cost of BAART HCV Implementation Project
Projected Annual Cost of Treating
HCV in SF
Projected Annual Savings of BAART
HCV Project Intervention
Annual Cost of BAART HCV Project
ROI of BAART HCV Project

$13 million
20% or $2.6 million
$106, 473
$24.42
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Appendix H: Communication Flow

INFORMATION

AUDIENCE

TIME

METHODS OF
COMMUNICATION

DNP Project Status

DNP Chair
MD at BAART
NP at BAART
DNP Student

Weekly

Email
In-person meetings
Phone

Changes/Revisions of
DNP Project

DNP Chair
MD at BAART
NP at BAART
DNP Student

Weekly
Continuous

Email
In-person meetings
Phone

Barriers/Issues/Resolutions DNP Chair
with DNP Project
MD at BAART
NP at BAART
DNP Student

Weekly
Continuous

Email
In-person meetings
Phone

Milestones to DNP Project

Continuous

Email
In-person meetings
Phone

DNP Chair
MD at BAART
NP at BAART
DNP Student
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Appendix I: GANTT Chart
Project GANTT
2018
Task/description
Meet with stakeholders
Complete literature review,
analyze available evidence,
meet with appropriate HCV
experts
Conduct chart reviews and
identify patients who
qualify for treatment
Provide education session to
counselors
Implementation of HCV
treatment program at
BAART
Data collection and analysis
Dissemination of project
results
Complete written DNP
Project

2019

Jan 2018
Jan-Feb 2018

March-June 2018
April 2018
June 2018
October 2018

Jan-Feb 2019
Feb 2019
May 2019
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Appendix J: BAART Staff Satisfaction Survey

Thank you in advance for completing this survey! I value your honest thoughts, feelings, and
experiences regarding the implementation of the Hepatitis C Treatment Program at BAART
Turk.
Please use the numeric scale 1-5, ‘1’ being ‘very unlikely’ and ‘5’ being ‘very likely’ to rate your
experience.
1) How sustainable and feasible do you feel the current model (policies and procedures) of
the Hepatitis C Treatment program is at BAART?
1

2

3

4

5

If less than ‘3’, please state why:

2) How likely did the Hepatitis C Treatment Program at BAART contribute to its overall
improvement of Hepatitis C patients?
1

2

3

4

5

If less than ‘3’, please state why:

3) How likely is it that improvements and/or changes could be made to the current
Hepatitis C Treatment Program model at BAART to make it better?
1

If less than ‘5’, please state why:

2

3

4

5
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Appendix K: BAART Patient Satisfaction Survey

Thank you in advance for completing this survey! We value your thoughts, feelings, and
experiences, and want to provide you the best care.
Please use the numeric scale 1-5, ‘1’ being ‘highly dissatisfied’ and ‘5’ being ‘highly satisfied’ to
rate your experience with the hepatitis C treatment program at BAART Turk.
1) Were you satisfied with the medical provider care and counseling you received?
1

2

3

4

5

2) How satisfied did you feel about the ease of obtaining and receiving your hepatitis C
treatment medications?
1

2

3

4

5

3) How satisfied were you with the cost of treatment?
1

2

3

4

5

4) How satisfied were you with the medication itself? (For example, did you experience any
side effects that made it challenging for you to adhere to the treatment regimen?)
1

2

3

4

5

5) Did you overall feel satisfied about the result of your hepatitis C treatment?
1

2

3

4

5

6) Based on your satisfaction with the hepatitis C treatment program at BAART Turk,
would you recommend this program to others?
Yes

No
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Appendix L: Counselor Training PowerPoint Slides
4/23/19

Objectives

Hepatitis C Education
BAART Turk
April 2018

What is Hepatitis C?

• Understand Hepatitis C (Hep C) basics

• Hepatitis C is a virus (Hep C) that affects the liver and

• List Hep C treatment process from start to finish
• Review how we (counselor and medical provider) will work

causes inflammation
-Hep C is transmitted through blood (e.g. sharing needles)
• Hep C affects over 3 million people in the U.S. (Hep C
Hope, 2015)

together to:
-Get BAART clients treated for Hep C
-Support process
• Learn client teaching points to prevent infection and/or reinfection of Hep C

• In SF, there are an estimated 12,000 people who live with
undiagnosed and untreated Hep C (End Hep C SF, 2017)
• Many of the people who are infected do not even know it!

Cara Nalagan, FNP-C, and Annie Pedlar, DNP-FNP
Student Intern

Who is at Risk for Hep C?

Being born between the years of 19451965 (Baby boomer)
Men who have sex with men (MSM)
People living with HIV
Transgender women
People with a history of incarceration

How is Hep C NOT Spread?

How is it Transmitted?

Current or past IV drug use (most
common mode of transmission)
Contact with infected blood or needles
(tooth brush, razor, nail clippers)
Tattoos or body piercings using nonsterile tools
Blood transfusion or organ transplants
before 1992

Coughing
Sneezing
Sharing food or water
Eating utensils
Breastfeeding
Hugging
Kissing
Holding hands

There is no vaccine for HCV, but the good news is it can be treated and cured!
End Hep C SF, October 2017

What are the Symptoms of Hep C?

Why are We NOT Aware We Have Hep C?
• For many, Hep C symptoms do not appear for
years or even decades.
• Many of us do not get tested because…
üWe do not know we are at risk
üThere is no vaccine for Hep C like there is for
Hep A and B, therefore Hep C is off our radar.
üIf your client is unable to be tested here, they
can go to Glide to have a fingerstick blood test
done to see if they have Hep C.

Hep C Treatment Process

• By the time symptoms appear, liver damage may have
already occurred.
• After a long period of no treatment of Hep C, the person
can go into liver failure and/or develop liver cancer, which
is very difficult to reverse and treat, and ascites (fluid buildup in abdomen).
• Symptoms include: fever, fatigue, loss of appetite,
nausea/vomiting, abdominal pain, dark urine, gray-colored

SCREENING

TREATMENT?
WHERE?

LABS

MEDICATION

CHECK FOR
CURE

PREVENT REINFECTION

bowel movements, joint pain, jaundice (yellowing of eyes
and skin), dry or itchy skin, sleep disturbances, depression,
“brain fog”.

1
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Has the Client Been SCREENED?
• Yes, the client has been screened with the appropriate Hep
C blood test and has been diagnosed as Hep C positive.

SCREENING

Does the Client Want TREATMENT?
If the client wants and agrees to treatment of their Hep C, it
needs to be determined who their insurance is and where
their primary care home is.

• If a blood test has not been completed, it is really important
that the Hep C blood test be done so that we can initiate
treatment evaluation for the client.

*RNA = viral load
World Hepatitis C Alliance, May 2014

20% of patients clear the virus on their own!

What if my Client has Hep C but Does Not Have
Primary Care Here at BAART Turk?

ØClient has primary care home…

ØClient does NOT have primary care home…

ØClient does NOT have primary care home…CONTINUED

No primary care home

Has Medi-Cal, but no primary care home
• Confirm which health plan client has: Anthem Blue Cross or
San Francisco Health Plan?

No health insurance
• Contact Medi-Cal

Primary care home at outside clinic: Tom Waddell, Curry
Senior Center, SFGH, etc.
-Notify BAART Turk NPs

• If none, enroll for San Francisco Health Plan
• Client to elect BAART Community Healthcare (Turk) as primary care home
• Client to enroll for primary care at BAART Turk with Lucy at Front Desk

-ROI signature to communicate w/client’s outside PCP
-NP to write referral letter for Hep C treatment for client’s
PCP & offer DOT of Hep C medication

Health Insurance Coverage

State Level ($)

Front Desk

SFHP Enrollment Services
Phone number is: (415)777-9992 OR (888)558-5858
Hours: Monday-Friday 8:30 AM-5:30 PM
There is also an email option available

Medi-Cal

Medi-Cal Health
Plan (HMO)

SFHP

Blue Cross

Primary Care
Home

BAART
Community
Healthcare
(Turk)

BAART
Community
Healthcare
(Turk)

• Client to elect BAART Community Healthcare (Turk) as
primary care home.
• Client to enroll for primary care at BAART Turk with Lucy at

Assessment Questions Prior to Treatment
Evaluation
• Prior Hep C treatment experience?
• Current medications?
• Does the client have liver cirrhosis?

2
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Lab Testing

Taking the MEDICINE

• Prior to starting Hep C treatment: blood tests are needed to
confirm diagnosis of Hep C, and to check for liver function
and other viral co-infections (Hep A & B, HIV) for treatment
evaluation.
*This has proven to be most challenging*

• At BAART Turk, we will be treating clients with a
medication called Mavyret, which treats the 6 genotypes of
Hep C.
• It is to be taken once daily (3 pills at one time), for every
day for 8-12 weeks.

Medication Side Effects
• There are very little side effects, the most common are
headache and fatigue (Epocrates, 2018)
• Other potential side effects include: nausea and diarrhea
(Epocrates, 2018)
• Side effects disappear within the first 2 weeks after the
medication is started

• Blood drawn at:
ü BAART medical department
or
üQuest Diagnostics Lab

Checking for Cure: Follow-up Blood Test During
Treatment

Importance of ADHERENCE to Medication Regimen
• Adherence to the medication regimen is KEY: Cure is
achieved in >95% of patients with 8-12 weeks of
medication therapy.
• The best way to promote adherence is by direct observed
therapy (DOT) or “window dosing” when the client is also
receiving their daily methadone dose.
• Clients w/methadone take-homes can receive Mavyret as
take-homes, max: 2 weeks’ worth at a time.

• Repeat blood test to check Hep C viral load:
•

At week 4 of treatment

•

At end of treatment (week 8 or 12)

Checking for Cure: SVR
6 months after treatment completion:
• Blood test for sustained virologic response (SVR) confirms
CURE
• The client will always have a positive blood test result for
the Hep C antibody (Ab), but the viral load (VL or RNA) will
be undetectable.

• SUPPORT/ENCOURAGE CLIENTS TO DOSE DAILY

Infection/Re-infection Prevention
• After successful treatment of Hep C, it is possible to
become re-infected!
• It is very important that we, as the clients’ support system,
provide education & resources about safe behavior to
reduce the risk of Hep C transmission and re-infection.

Infection/Re-infection Prevention

THANK YOU!

• According to End Hep C SF (2017), “you can protect
yourself and others from getting hepatitis C by getting
tested, talking about your status, and injecting safely”. All of

QUESTIONS?

these actions can reduce your risk of contracting or
passing the virus on to others.
• *See pamphlets*

3
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RN Algorithm: Patient Assessment for Treatment
Readiness
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Does pt have active HCV (2 VLs, 3 mos apart, and >1000 IU/mL)?
Yes
Is patient interested in
treatment?
Yes

No

If only one
viral load,
order repeat

Screening per OTOP protocol.
Risk reduction counseling with
conselor

No
Positive VL >1000

Does patient have regular primary care (seen ³ 2 times in past
year)?

Follow tx assessmt.

Yes

No

Obtain ROI to talk with
PCP

Insurance active?

E-mail to provider to inquire
about treatment

Yes

If provider interested in OTOP
assisting, follow remainder of
algorithm

Labs done? (CBC, chem, LFTs, genotype,
INR, vit D, hep B/A, HIV prn, UPT if
F<45oyo)

No
Refer for MediCal eligibility.
Alert counselor to assist client w/insurance.
Patient/counselor to request RN visit once
active.

Yes

No

Ultrasound done?

Order Labs (CBC, chem, LFTs, INR, vit D,
genotype, hep B cAb, hep B sAb, hep B
sAg, total hep A Ab, and HIV prn)

Yes

No

Refer to Dr. Azari for
treatment assessment

Order ultrasound
*note: U/S can be ordered at same time as labs

Make sure apt kept with Dr.
Azari

Not
sure

Once done, Refer to Dr. Azari for treatment
assessment
Make sure apt kept with Dr. Azari
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RN Algorithm: Patients Active on Treatment

Patient on DOT Treatment for HCV
Check Absent Records q
week
Patient has missed
³2 days per week?
Yes

No

Flag patient to
discuss
attendance/
adherence
Attendance
improved?
Yes

No

Continue
Per
Algorithm

Discuss
with Dr.
Azari

Continue per
algorithm

Flag patient for appointments and lab
checks
1 week: RN
visit for
adherence
/side
effects

4 weeks: RN visit
for adherence
check/side effects
& order labs (CBC,
LFTs, Creat, HCV
RNA viral load,
UPT prn)

Yes:
Significant
side effects
Discuss
with Dr.
Azari

12
weeks:
RN visit
for labs
(HCV
RNA
viral
load)

HCV viral load
detectable >200
IU/mL?
Yes

No

Repeat lab testing
at 6 weeks and
stop if HCV RNA
increasing. Inform
Dr. Azari

Continue to
monitor
per
protocol

If detectable >200 IU/mL,
continue meds additional 4
weeks

Ensure med
supply is
sufficient q
week: call
Daniels or US
Bioservices
Pharm as
needed
Discuss
with Dr.
Azari
PRN
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Appendix N: Evidence Table

Citation

Conce

Design/Met

Sample/Set

ptual
hod TREATMENTting
HCV
OUTREACH
PROGRAM

Asselah, T.,
Kowdley, K.V.,
Zadeikis, N.,
Wang, S.,
Hassanein, T.,
Horsmans,
Y.,…Mensa,
F.J. (2017).

Variables

Measure

Studied and

ment

Frame

their

work

Definitions

N/A

Three-part study,
two studies being
open label, and
single-arm, and the
other being a
randomized,
double-blind,
placebo-controlled
study

Total of 568
patients with
HCV genotype
2,4,5, or 6
infection
without cirrhosis
in 3 separate
phase trials.

IV: Chronic HCV
with either
genotype 2,4,5, or
6, absence of liver
cirrhosis, may or
may not have
been treated with
antivirals prior.

SVR12 after 8
weeks’ and 12
weeks’
treatment

DV: SVR12 at 8
weeks’ and 12
weeks’ time.

Wyles, D.,
Poordad, F.,
Wang, S.,
Alric, L.,
Felizarta, F.,
Kwo,
P.Y.,…Lee, S.
(2017).
Glecaprevir/
pibrentasvir
for hepatitis
C virus
genotype 3
patients
with
cirrhosis
and/or prior
treatment

N/A

Partially
randomized,
open-label,
multicenter,
phase 3 study

131 patients
with HCV
genotype 3 with
prior treatment
experience
and/or liver
cirrhosis.

IV: HCV genotype
3, prior treatment
experience,
treatment-naïve,
liver cirrhosis.
DV: SVR12

SVR12 of 12 or
16-week
treatment
regimen

Findings

Appraisal
88

At 8 weeks,
SVR12 98%
for HCV
genotype 2,
and 93% for
HCV
genotypes
4,5, and 6. At
12 weeks,
SVR12 99.5%
for genotype
2, and 99%
for genotypes
4,5, and 6.

Level I, B

In treatment
experienced
patients
without
cirrhosis, an
SVR12 was
attained by
95% of patients
treated with
Mavyret for 12
or 16 weeks.
The patients
who had
cirrhosis and
were
treatmentnaïve achieved
an SVR12 of

Level II, B

Weaknesses: no age specified of patient’s, unsure how
many patients had been treated for HCV prior to this
course, unsure how many patients had compensated
liver cirrhosis, unable to determine history of HBV, no
ratio of sex and age listed.
Strengths: sufficient sample size of 568, strong study
design (RCT, double-blind, placebo-controlled),
treated genotypes 2,4,5, and 6, no adverse events
from Mavyret.

Weakness: Conflict of interest, some of the authors
receive grants from AbbVie, the makers of Mavyret,
age of p tot specified, unknown how advanced liver
cirrhosis is, unknown reasons why prior medicaiton
regimens for treating HCV did not work (patient nonadherent)., unable to determine history of HBV.
Strengths: Multicenter, no adverse events from
Mavyret,
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experience:
A partially
randomized
phase 3
clinical trial.
Hepatology,
67(2), 514523. Doi:
https://doi.
org/10.1002
/hep.29541

Rockstroh,
J.K,
Lacombe, K.,
Viana, R.M.,
Orkin, C.,
Wyles, D.,
Luetkemeye
r,
A.,…Sulkows
ki, M.
(2018).
Efficacy and
safety of
glecaprevir/
pibrentasvir
in patients
coinfected
with
hepatitis C
virus and
human
immunodefi
ciency virus
type I: The
EXPEDITION2 Study.
Clinical
Infectious
Diseases.
Retrieved

98% at 12
weeks, and
96% of the
patients with
prior treatment
experience
attained an
SVR12 who
were treated
for 16 weeks.

N/A

Phase 3,
multicenter,
open-label study

153 patients, 16
with cirrhosis,
HCV/HIV
coinfection,
genotypes 1-6,
treatment-naïve
or experienced,
cirrhosis present
or not.

IV: HIV and/ or not
taking
antiretrovirals,
HCV genotypes 16, treatment-naïve
or experienced,
liver cirrhosis
present or not.
DV: SVR12

SVR12

SVR12 rate
98% with no
virologic
failures in
137 patients
treated for 8
weeks. 4
patients had
adverse
events, not
due to
Mavyret.

Level II, B
Weaknesses: Not clear on why of the 153 patients 137
were treated, unclear as to how cirrhotic the patients
were, no age range, male:female ratio, unable to
determine history of HBV.
Strengths: Multicenter, excluded genotype 3 patients
with experience of treatment since could unfairly sway
results, good sample size, treated genotypes 1-6.
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from
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rmark.silver
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y220.pdf?to
ken=AQECA
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wggGtBgkqh
kiG9w0BBwa
gggGeMIIBm
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MGCSqGSIb
3DQEHATAe
BglghkgBZQ
MEAS4wEQ
QMsat_nwn
nB98hGF7CA
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vhaoydNlqA
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_jDLkCs8xke
CIYNEebVpJc
dYHCF0ZXGS
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oZZlSoxrqgG4tOmw
uaKViH1YCRj
FVAqLzcGGp
eS7n98b4dE
WT8w7k9Yd
ud6vyvF_G3
T5DRsPqlve
oBdEAPWW
ay19vhRvJL5
UgOo7cA9Pt
u44wKQxCD
N13bbm5Da
keGebgG4M
nvmwscBgWOgevpPD
IzE3nzwFaU
OARGcz3rtfp
CtX5PiwnED
TuGiQGltwAl
eNBuiK6YN4
1x5NX0_qEq
9SDUo5e_ilB
JoJhe

Poordad, F.,
Felizarta, F.,
Asatryan, A.,
Sulkowski,
M.S.,
Reindollar,
R.W.,
Landis,
C.S.,…Mensa
, F.J. (2017).
Glecaprevir
and
pibrentasvir
for 12 weeks
for hepatitis
C virus
genotype 1

N/A

Phase 2, openlabel study with 3
arms

50 patients with
HCV, genotype
1, history of DAA
virologic failure.

IV: HCV, genotype
1, history DAA
with virologic
failure.
DV: SVR12

SVR12

Of the 3
arms, arm A
had an SVR12
of 98%, arm B
had 95%, and
arm C had
86%. Results
were
indicative
that Mavyret
is highly
effective in
type 1
genotype
patients with
a history of

Level II, B
Weaknesses: only genotype 1 treated, small study of
50 patients, age not specified, history of HBV not
indicated, male:female ratio unknown.
Strengths: no adverse events caused by Mavyret or
ribavirin
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infection
and prior
direct-acting
antiviral
treatment.
Hepatology,
66(2), 389397. doi:
10.1002/hep
.29081
Chayama,
K., Suzuki,
F.,
Kawakami,
Y., Sato, K.,
Atarashia,
T.,
Naganuma,
A.,…Kumada
, H. (2017).
Efficacy and
safety of
glecaprevir/
pibrentsavir
in Japanese
patients
with chronic
genptype 1
hepatitis C
virus
infection
with and
without
cirrhosis.
Journal of
Gastroenter
ology, 53(4),
557-565.
doi:
10.1007/s00
535-0171391-5

DAA virologic
failure.

N/A

Phase 3, openlabel, multicenter
study with 2 arms

Total of 181
patients with
HCV genotype 1,
with or without
cirrhosis.

IV: HCV, genotype
1, presence or
absence of liver
cirrhosis.
DV: SVR12

SVR12 after
the 8 weeks’
and 12 weeks’
treatment
completion.

SVR12 in
99.2% of noncirrhotic
patients, and
100% in
cirrhotic
patients after
course of
Mavyret.

Level II, B
Weaknesses: only genotype I, undetermined if history
of HBV, unable to determine if treatment-naïve or
experienced, no age range, no male:female ratio
listed.
Strengths: No virologic failures observed, no adverse
events from Mavyret, multicenter, sufficient sample
size.
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Kwo, P.Y.,
Poordad, F.,
Asatryan, A.,
Wang, S.,
Wyles, D.L.,
Hassanein,
T.,…Mensa,
F.J.
Glecaprevir
and
pibrentasvir
yield high
response
rates in
patients
with HCV
genotype 16 without
cirrhosis.
Journal of
Hepatology,
67(2), 263271. doi:
10.1016/j.he
p.2017.03.0
39

N/A

Forns, X.,
Lee, S.S.,
Valdes, J.,
Lens, S.,
Ghalib, R.,
Aguilar,
H.,…Mensa,
F.J. (2017).
Glecaprevir
plus
pibrentasvir
for chronic
hepatitis C
virus
genotype
1,2,4,5, or 6
infection in
adults with
compensate

N/A

2 studies; phase
II, open-label,
multicenter, doseranging trials

Single-arm, openlabel, multicenter
phase 3 study
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Total of 449
patients, chronic
HCV with
genotypes 1-6,
no cirrhosis.
Treatment-naïve
or prior
exposure to
interferon and
ribavirin.

IV: chronic HCV,
genotypes 1-6,
treatment-naïve,
previous
treatment
exposure to
interferon and
ribavirin.

Total of 146
patients, 18 or
older, chronic
HCV with
genotypes
1,2,4,5, or 6,
treatment- naïve
or treatment
exposure,
compensated
cirrhosis.

IV: chronic HCV
with genotypes
1,2,4,5, or 6,
compensated
cirrhosis,
treatment-naïve
or previous
exposure, age
over 18.

SVR12 after 8
and 12 weeks’
treatment

DV: SVR12

DV: SVR12

SVR12 after 12
weeks’
treatment

SVR12
attained in
97-100% of 8weeks’
treatment,
and 97-98%
in 12-weeks’
treatment.
High SVR12
response rate
achieved.

Level II, B

SVR12
attained in
99% of
patients after
taking 12week course
of Mavyret.
Favorable
safety profile
and high
SVR12
response
rate.

Level II, B

Weaknesses: unable to determine if history of HBV,
adverse events from medication present (unclear as to
what caused AE), no age range listed.
Strengths: multicenter, all 6 genotypes, dose-ranging,
large sample size.

Weaknesses: Potential conflict of interest since study
was funded by AbbVie, the manufacturer of Mavyret,
genotype 3 excluded, unclear if history of HBV,
male:female ratio not listed.
Strengths: age range listed, all patients treated for 12
weeks.
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d cirrhosis
(EXPEDITION
-1): a singlearm, openlabel,
multicenter
phase 3
trial. Lancet
Infectious
Disease,
17(10),
1062-1068.
doi:
10.1016/S14
733099(17)304
96-6
Gane, E.,
Poordad, F.,
Wang, S.,
Asatryan, A.,
Kwo, P.Y.,
Lalezari,
J.,…Mensa,
F.J. (2016).
High
efficacy of
ABT-493 and
ABT-530
treatment in
patients
with HCV
genotype 1
or 3
infection
and
compensate
d cirrhosis.
Gastroenter
ology,
151(4), 651659. doi:
10.1053/j.ga

N/A

2 open-label
phase 2 studies

27
patients
with
genotype
1 and 55
patients
with
genotype
3, majority
treatment
-naïve
(84%) and
male
(65%).

IV: Chronic HCV
with either
genotype 1 and 3,
compensated
cirrhosis,
treatment-naïve,
treatment
experienced, sex.
DV: SVR12

SVR12

SVR12 among
genotype 1
was 96% and
among the
genotype 3
patients an
SVR12 of
96%. High
SVR12
response
rate, between
96-100%.

Level II, B
Weaknesses: study exclusive to genotype 1 and 3,
history of HBV unknown, treatment between 12 and
16 weeks (variability).
Strengths: sufficient sample size, multicenter, listed
sex ratio, listed percentage who are treatment-naïve,
all patients had compensated liver cirrhosis.
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Berg, T (2018).
First real-world
data on safety
and effectiveness
of
glecaprevir/pibre
ntasvir for the
treatment of
patients with
chronic hepatitis
C virus infection:
data from the
German hepatitis
C registry.
Pharmacy &
Therapeutics,
43(6), 362-366.
Retrieved from
https:/
/www.ncbi.nlm.n
ih.gov/pmc/articl
es/PMC5969214/

N/A

D’Ambrosio, R.
Real-life
effectiveness
and safety of
glecaprevir/pib
rentasvir
among 723
patients with
chronic HCV:
The navigator-II
study.
Pharmacy &
Therapeutics,
43(6), 362-366.
Retrieved from
https://www.nc
bi.nlm.nih.gov/

N/A

Phase-3 clinical
trial

Phase-2 clinical
trial

Total of
638
patients
(68%
male,
median
age 47
years),
treatment
naïve
(90%)
without
cirrhosis
(93%).
Treated
for 8weeks
(92%) with
Mavyret.

IV: Chronic HCV
with genotype 1-6,
compensated
cirrhosis, noncompensated
cirrhosis, sex, age,
treatmentexperienced,
treatment-naïve.

Total of
723
patients;
interim
results of
347
patients.
Patients
treated
for either
12 or 16
weeks.

IV: chronic HCV,
treated with
Mavyret, sex, age.

SVR12 after 8weeks
treatment

DV: SVR12

DV: SVR4 and no
presence of viral
load (VL) at end of
treatment,
indicating that
HCV is
undetectable.

SVR4 after 12or 16-weeks
treatment
with Mavyret.
VL at end of
treatment.

The SVR12
after an
interim
analysis of a
modified
intention-totreat
population
excluding
nonvirological
failures was
100% (49
of49)
confirming
the high cure
rates of 98%
in other
phase 3 trial
studies.

Level II, B

The interim
results
indicate that
the
effectiveness
and safety
profile of
Mavyret are
excellent
across a
range of
different
patient types.

Level II, B

Weakness: treatment-experienced patients treated
with what antiviral, unclear as to why patients who
were treatment-experienced were being treated
again, unclear as to which genotypes were treated.
Per the conclusion of the study, there is lack of data in
the difficult-to-treat genotype 3 patients, results
drawn from a smaller section of the study (49
patients), no age range listed, not stated why some
patients were treated for 12-weeks vs 8-weeks.
Strengths: large sample size of the initial study (638),
male and female patients, average age provided,
percentage of treatment-naïve, without cirrhosis, and
how many patients treated for 8-weeks.

Weaknesses: Unsure of which genotypes were treated,
age range not listed, does not label if the patients
treated were treatment-naïve or not, no clear result if
an SVR12 was ever attained, does not identify results
of fibrosis scores (did some patients have
compensated liver, decompensated liver?).
Strengths: large sample size (723), interim size large
(347), mean age listed, percentage of male patients
listed.
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